corporate responsibility report human race feel better live longercorporate responsibility report introduction introduction corporate responsibility gsk access medicine research ethical conduct employment practices supply chain environmental management work communities data summary gsk corporate responsibility report corporate responsibility report introduction welcome glaxosmithklines corporate responsibility report report explains approach wide range social ethical environmental issues associated business performance gsk report medicines researchbased pharmaceutical report covers corporate responsibility key pharmaceutical products company mission improve activity performance updates target serious diseases including quality human life enabling people last corporate responsibility report published asthma chronic feel better live longer business march obstructive pulmonary disease employs people countries epilepsy depression data relate calendar year except consumer healthcare business includes dental health diseases central nervous stated products overthecounter medicines system nutritional drinks environmental data cover calendar year hivaids herpes data collected viral diseases key statistics pharmaceutical consumer manufacturing infections sites biologicals manufacturing sites bnexcept diabetes operation pharmaceutical employees consumer research development sites cancer turnover total major office locations include available data heart disease sites operation part cardiovascular diseases pharmaceuticals year require environmental data urogenital diseases consumer healthcare small offices distribution centres notes attached charts explain scope data profit taxation collection process parameter detail vaccines number unless specified per unit sales figures gsk makes vaccines protect employees absolute numbers ie total consumption diseases including energy water etc data environment health hepatitis b safety sections report externally diphtheria turnover location customer verified see verification influenza scope data relate worldwide polio operations except indicated rotavirus bn use external guidelines frameworks tetanus inform reporting relevant typhoid base report global reporting initiative bn guidelines produced gri indexto whooping cough show elements guidelines cover aid comparison company reports bn consumer healthcare brands background information policies brands include approach cr available website overthecounter medicines wwwgskcomresponsibility beechams contac nicoretteniquitin panadol also publish corporate responsibility review tums zovirax usa bn provides overview approach dental health aquafresh corporate responsibility available print europe bn macleans polident sensodyne website nutritional drinks horlicks international bn cr report one top reports lucozade ribena ranked th sustainability united nations environment programme standard poors global reporters survey international benchmark survey nonfinancial reporting gsk corporate responsibility report corporate responsibility report ceochairmans letter believe healthcare company isnt sustainable concerned percent worlds population lucky enough resources pay new treatments believe access medicines essential vision gsk improving peoples health drives us makes talented scientists want work commitment poorest countries integral countries may represent viable commercial market new medicines still need people medicines afford yet pure philanthropy right solution either needs great look new ways tackle problems gsk involved ten public private partnership projects researching new medicines vaccines diseases disproportionately affecting developing countries including hivaids malaria tb also making key medicines vaccines accessible discounted prices negotiated eight licences thirdparty manufacturers produce generic versions key hiv medicines report shows efforts starting bear fruit preferential pricing voluntary licences helping increase supply hivaids medicines subsaharan africa seven countries completed fiveyear programmes eliminate lymphatic filariasis using albendazole treatment continue donating tablets disabling incurable disease completely wiped vaccines another exciting area percent vaccine doses produced sold preferential prices immunisation campaigns developing world save millions lives expect launch vaccine cervical cancer disease affects women countries greatest impact developing world screening programmes catch early cases room complacency much effort needed stakeholders resolve healthcare problems developing countries proud contribution making know efforts access medicine must based solid foundation industry high profile often subject criticism good medicines make big difference quality length life us rightly expected meet highest standards integrity aspects work report gives snapshot approach embedding ethical culture across gsk includes applying highest standards behaviour transparency rd promotion medicines treating people well minimising impact business environment also need play part tackling major global issues climate change value input stakeholders would welcome views report aspects corporate responsibility gsk sir christopher gent jp garnier chairman chief executive officer gsk corporate responsibility report corporate responsibility report qa duncan learmouth appointed senior vice president corporate communications community partnerships sets vision cr gsk complete qa available full cr report wwwgskcomresponsibility vision cr gsk gsks programmes developing three elements want achieve high world philanthropy part standards behaviour everything business parts company want known theres doubt part business weve adopted theme performance need medicines go away integrity successful need make sure programmes engaging employees secondly need sustainable best way make bring outside world decision making sure part daytoday business full understanding stakeholder great example longterm commitment views make best decisions third providing notforprofit hiv medicines element desire real member worlds poorest countries also local community everywhere operate immense stakeholder pressure subject includes playing part wider global would impossible turn blind eye community contributing better healthcare responding pressure outside employees want work think gsk well company addressing challenges engaged issues developing duty use scientific knowhow world experience quite unusual human capital make difference public company believe lead essential sense integrity industry rd neglected diseases preferential pricing voluntary licensing well ahead havent reduced price sectors take longterm products markets approach programmes involve high sustainable business make degree partnership dialogue ngos adequate return wont able discover governments organisations world new medicines immense pressure health organisation gates foundation competitors investors nevertheless looking issue pricing beyond worlds gsk poorest countries sales marketing practices always hot topic pharmaceutical industry need ensure researching new medicines keep public regulatory really needed looking expectations market products drugs ensure gsk policies meet exceed changing many cases drugs really needed expectations however first change profitable thats commercial practices runs risk reducing demand new drugs cancer alzheimers competitiveness must also proactive meeting huge unmet medical need encouraging others industry follow suit profitable problem diseases tend present extreme scientific challenges biggest challenge require novel scientific approaches carry difficult task finding balance greater risk failure diseases developing needs different stakeholders investors world present different problem great concerned primarily profit cr important need viable commercial market new affects longterm success products get round problem working company next quarters earnings public private partnerships often pressing priority hand active rd neglected tropical diseases think ngos others society would like us debate metoo drugs taken concerned solving societys healthcare far new drug enables patients take fewer problems doses day reduces side effects may seem like small improvement make big difference treatment outcome gsk corporate responsibility report corporate responsibility report pharmaceutical industry role gsk playing addressing criticised lack transparency climate change clinical trial results targets reducing energy usage anything address concern believe weve adopted sustainable approach perception pharmaceutical linked business position industry less transparent think company addresses healthcare needs partly havent done good job relatively small footprint communicating challenges face believe compared sectors issues online clinical trial register gone higher priority address nevertheless way addressing concerns climate change important issue gsk communication data clinical trials stakeholders need play part tough area weighing balance risks tackling benefits medicine rarely straightforward data isnt black white requires interpretation judgement inevitably means people different views knowledge change time new drugs tested used actually talking medicines doctors straightforward communication important challenging pharmaceutical industry sustainable contract society return investing new drugs generally around ten years intellectual property protection products generics made rd uncertain unpredictable periods successful others believe basic model still good one fosters high level innovation course challenges industry must continually look ways improve rd productivity unique type product plays personal role peoples lives nowadays good health seen right also business people uncomfortable generally though believe people accept need tradeoff may like us making profit health accept best way encourage discovery new medicines gsk corporate responsibility report corporate responsibility report corporate responsibility gsk cr important gsk strategy corporate responsibility gsk committed addressing two key challenges achieve goals implement facing pharmaceutical industry society business strategy aim operate way whole reflects values understanding improving productivity research responding stakeholder views connecting development business decisions ethical social environmental concerns part support patient access new medicines corporate responsibility helps achieve business goals focus four business strategies structured report around strategies supporting relationships key show corporate responsibility integrated stakeholders including patients consumers business doctors governments protecting enhancing reputation therefore trust products improving ability attract retain motivate best people strengthening risk management processes believe business makes valuable contribution society developing marketing medicines improve peoples lives however know research development manufacture sale medicines raise ethical issues seek minimise negative impacts business maximise positive benefits products operations build best product pipeline industry maximise potential current product benefit patientsconsumers society portfolio relevant responsibility issues include relevant responsibility issues include animal research ethical conduct conduct clinical trials standards supply chain patient safety environmental impact interactions patient groups improve access medicines developed best place best people developing world best work relevant responsibility issues include relevant responsibility issues include rd diseases developing world employment practices preferential pricing diversity voluntary licensing human rights employees supply chain access medicines middle income developed health safety countries resilience well community investment gsk corporate responsibility report corporate responsibility report important corporate responsibility dtc advertising issues consistency commercial practices codes corporate responsibility broad subject covers wide range issues need committee also reviews signs prioritise issues order manage annual cr report effectively report clearly performance cr risks identify important material issues management significant business risks gsk engagement stakeholders coordinated risk oversight compliance risk management processes knowledge council rocc rocc also considers business pharmaceutical industry reputational corporate responsibility risks inputs led us identify four cr issues background information rocc particularly relevant significant gsk see risk management compliance gskcom research innovation contributing management structure healthcare developing medicines duncan learmouth senior vice president corporate vaccines meet needs patients communications community partnerships rupert bondy general counsel executive access medicines developed team members responsibility cr developing countries believe daytoday management cr ethical conduct including sales marketing issues done effectively within business practices operations experts cr issues work environment including climate change coordination provided crossfunctional team impact pharmaceuticals environment made representatives key business areas representatives senior managers direct access appropriate executive team member role oversee development managing cr implementation communication cr policy across gsk ensures comprehensive corporate responsibility statement consistent approach taken throughout principles define approach key cr issues organisation provide guidance employees standards company committed also small cr team coordinates view principlesin background section policy development reporting communication website socially responsible investment analysts cr governance details environment health safety corporate responsibility committee management see ehs management crc nonexecutive board directors provides assurance highlevel guidance approach cr environment health safety sections ceo members corporate executive team report externally verified environmental actively involved cr participate crc assurance consultancy sgs purpose meetings assessment committee members sir christopher gent check ehs data presented accurate chair sir ian prosser dr daniel podolsky tom represent gsks performance de swaan find information fairly crc members terms reference background sectionof website critically review completeness relevance information presented committee meets four times year review policies progress cr principles four assess effectiveness gsks data principles access medicines standards ethical management reporting systems conduct research innovation global find sgss verification statement community partnerships reviewed annually response principles discussed least every two years committees findings reported sections report externally board verified however gsk extensive internal audit programme covers aspects committee reviewed activity business number areas including internal communication awareness access medicines keep employees informed corporate community investment responsibility copies cr overview brochure distributed reputation management employees directly spirit internal caring environment magazine spirit also features regular articles cr related topics standards ethical conduct gsk corporate responsibility report corporate responsibility report also surveyed random selection difficult quantify extent employees awareness corporate engagements since activity embedded responsibility issues consider business operations included examples important employees across section throughout report world different areas business ways engaged responded survey stakeholders percent heard corporate investors benchmarking organisations responsibility held meetings investors discuss cr issues percent recognised responsibility employees included onetoone meetings discuss key issues well educational visits meetings ethical business conduct access medicines january hosted meeting investors health safety three areas vaccines facility belgium investors shown identified important presentation science vaccines visited also areas employees believe sites research production areas october company address eight investors visited manufacturing plant dartford england investors shown process making active ingredients products environmental management facilities plant occasions investors stakeholder engagement opportunity meet question senior stakeholder engagement important gsk staff component approach managing december gsk dresdner bank ran business responsibly helps us identify educational seminar patient safety important cr issues business understand investors senior physician charge stakeholder views expectations build global patient safety explained current drug trust key audiences also engage safety monitoring procedures gsk plans stakeholders tell work develop answered questions learn expertise gsk interacts wide investors range stakeholders including investors raise questions issues throughout patients year main issues raised related sales doctors marketing practices climate change access medicines clinical trials ethics particularly governments regulators developing world approach issues public private health providers found report ngos multilateral organisations employees investors local communities suppliers scientific community peer companies discussion takes place normal course business example scientists meet regularly academics researchers pharmaceutical companies gsk corporate responsibility report corporate responsibility report gsk received following ratings agencies organisation rating association british insurers gsk given full rating disclosure board responsibilities policies relating socialethical environmental issuesthis highest possible rating dow jones sustainability index gsk included years indexindividual company scores rankings longer published ftsegood index gsk included ftsegood index innovest strategic value advisors rated rd companies innovests global pharmaceutical sector reportgsk rated particularly highly area strategic governance claremont mckenna gsk received b rating pharmaceutical sustainability reportingcarried claremont mckennaa us college evaluates companies corporate responsibility issuesgsk thout companies evaluated gsk reported greenhouse gas emissions thoughtout well managed rated carbon disclosure project cdp read highly programmes increase access response cdp website medicines developing world wwwcdprojectnet opinion leaders made suggestions cr benchmark studies improve number areas cosponsored benchmarking study included consultancy thinktank sustainability non gsk demonstrate commitment financial reporting pharmaceutical industry improving health globally beyond selling gsk rated highest overall compared pharmaceuticals eg disease companies sector prevention also ranked th top embed cr throughout companies sustainabilityunep global company set targets improve reporters study best practice sustainability performance reporting gsk one two pharmaceutical companies top gsk spend time listening stakeholders retained position premier league companies scoring percent business develop strategy reducing communitys environment index impact climate change ehs focus improving access established stakeholder panel inform medicines middleincome countries approach ehs management made reporting ten external stakeholders representing customers opinion leaders felt gsks cr report covered suppliers regulators public interest groups right issues report long overall investors well four senior gsk ehs reducing readability gsk scored points representatives improving transparency reporting opinion leaders last three years stakeholders expected opinion leaders influential individuals disclosure gsks work patient advocacy organisations expertise corporate groups ethics management supply chain responsibility include ngos government approach human rights issues representatives investors journalists academics stakeholders consumer industry organisations following table summarises interaction held two discussions one us groups shows information uk gather feedback opinion leaders found cr performance reporting performance participants mostly agreed gsks approach corporate responsibility comprehensive well gsk corporate responsibility report corporate responsibility report stakeholder engagement ngos engage international community ngos accesseducation public health programmesread investment public health initiatives community investmenton also engage regularly animal welfare organisations read animal researchon employees seek feedback employees regular employee surveys see employmenton summary results latest survey also consult employees changes affect discuss business developments works councils european employee forumfor information see internal communicationson governments engage debate legislation seek influence policy decisions affect gsk regulators also engage governments advance corporate responsibility objectives see government external affairson multilateral agencies engage multilateral agencies access public health initiatives see access medicineson doctors engage doctors many ways including medical representatives running clinical trialssee researchand ethical conduct information manage issues engagement raises patients gsk researchers scientists meet patients part focus patient initiativethis engagement influences understanding diseases research priorities also engage patient groups directly patient advocacy leaders summitsread patient advocacy also conduct market research via third parties understand patient needs local communities interactions local communities managed individual gsk sites see working communitiesfor examples initiatives suppliers hold global regional supplier review meetings senior gsk managers address interact suppliers key issuesfor information see supply chain scientific important gsk part scientific academic debatesthis report contains community examples interactionsfor discussion manage academic partnerships relationships see research gsk corporate responsibility report corporate responsibility report government external affairs pharmaceutical industry highly regulated common european regulatory system regulations significant impact offers rapid approval new products business essential engage intellectual property incentives promote debate legislation seek influence policy research orphan medicines paediatric decisions affect gsk fact major medicines medicines developing multinational corporation often approached world governments give views along stakeholders ngos implementation clinical trial regulations promote safety good clinical practice size global reach give us access governments policy makers need use appropriate use health technology access responsibly benefit patients assessments htas believe htas business believe transparent independent transparent scientifically lobbying public policy work robust means ensuring increase stakeholder trust confidence gsk right medicines reach right people rather used rationing tool policies governing interactions important stakeholders section covers increased individual involvement interaction governments external responsibility personal healthcare including groups including patient advocacy groups improved access information information approach working medicines pharmaceutical companies doctors healthcare professionals available environment promotes research research sectionof report development encourages informed debate background information approach benefits challenges new research public policy available external affairs technologies sectionof gskcom advocacy cr issues approach external affairs engage governments gsks external affairs teams monitor changes stakeholders advance corporate responsibility proposed reforms legislation meet regularly objectives example gsk government officials explain views advocated improvements healthcare range public policy issues lobbying issues developing world discussions affecting whole pharmaceutical industry uk us governments multilateral sometimes conducted trade associations agencies ngos see access medicines may also hire professional lobbyists support public policy work participated world aids conference held toronto canada see access medicines public policy work governed external affairs code conduct backed supported mobilising malaria advocacy factual research analysis see policy initiative generate political commitment background site sustained funding combat malaria see community investment gsk believes legally culturally appropriate political donations legitimate way worked regulators encourage supporting political process information acceptance alternatives animal testing see donations given report animal research annual report accounts political participated developing world health donations policygoverning contributions organizations international clinical trials political candidates registry platform initiative standardise public policy activity way information medical studies engaged governments wide made available public range issues affect industry particular encouraged consistent approaches advocated policies deliver patient safety reporting side effects strong intellectual property rights data see patient safety exclusivity protection encourage research led efforts develop industry codes conduct development new medicines marketing ethics several asian countries vaccines see marketing codes practice pricing reimbursement systems support innovative medicines provide greater predictability transparency believe greater liberalisation pharmaceutical pricing especially medicines paid governments gsk corporate responsibility report corporate responsibility report position key issues publish position many key issues gsk make donations political parties background sectionof website happy political organisations european union discuss position issues see annual reportfor information legitimate parties contact corporate contributions united states responsibility team csrcontactgskcom us candidates financed primarily current position statements published contributions companies individuals ngos wwwgskcomresponsibilityinclude parties corporate contributions accepted important way companies clinical trials developing countries engage political debate counterfeit medicines corporate contributions national political parties developing world challenges access candidates running federal office medicines prohibited us law importation medicines contributions state candidates gsk corporate funds given candidates intellectual property trips agreement state level states permitted product diversion law donated approximately candidates stateheld offices preparations flu pandemic split republicans approx percent membership trade associations democrats approx percent gsk member trade organisations including contributions made basis association british pharmaceutical political party gsk supports candidates seek industry abpi environment appropriately rewards high risk highinvestment industries believes free biotechnology industry organization bio market principles intellectual property rights european federation pharmaceutical states publish information political industries efpia donations intellectual property owners association ipo political action committee contributions accordance federal election campaign japan pharmaceutical manufacturers act gsk political action committee pac association jpma facilitates voluntary political contributions swedish association pharmaceutical eligible employees pac controlled gsk industry lif participating employees legal right make contributions candidates organization international investment ofii political parties federal state levels pharmaceutical research manufacturers pac contributions voluntary donations america phrma subject strict limitations example gsk pac may contribute excess international federation pharmaceutical candidate federal office per election manufacturers associations ifpma pac contributions determined governing us lobbying expenditures board pacparticipating gsk employees gsk spent federal lobbying activities across company required law pac us information reported contributions reported federal elections us congress accordance lobbying commission fec second half disclosure act includes costs twoyear federal election cycle gsk employees salaries benefits employees registered pac contributed candidates state lobby us government hiring outside lobbying federal offices consultants support lobbying contacts planning activities research background contributions canada running gsk washington dc government gsk donated cad approximately affairs office support staff portion trade canada political candidates association fees associated federal lobbying provinces legal countries collect separate data contributions countries lobbying expenditure gsk donated aus approx australia political donations gsk makes political donations corporate funds patient advocacy authorised law culturally patient advocacy groups provide members appropriate support information live condition represent patient views contributed political advocate issues affecting patients interests organisations us canada australia important stakeholder gsk donations covered gsk policy engage part aim patient political donations focused company gsk corporate responsibility report corporate responsibility report principles working across world work wide range work patient groups patient groups patient groups variety different disease areas patient advocacy leaders summits pals one independence cancer asthma diabetes hivaids ways engage patient groups patient associations interest patient advocacy understanding held summits us japan many political judgement patient needs illness aim support european countries including poland netherlands activities shall assured voice patients thus encourage romania latvia meetings give patient constructive healthcare debate stakeholders groups opportunity learn gsk tell cooperative matters company better support work transparency vital believe patient groups playing discuss debate key issues relating patient joint policies increasingly valuable role improving healthcare advocacy healthcare policy typically undertaken protect independence credibility patient range workshops attendees including patients associations groups encouraged obtain support glaxosmithkline shall sessions media training sharing best practice financial nonfinancial diverse multiple based mutual respect sources private public individual european patient group advisory board trust donations consult gsk policies thus work glaxosmithkline shall make company patientcentric possible refrain using undue approach board independent chair made influence promote committed ensuring work specific medicines patient groups highest levels ethical representatives series european groups services many disease areas gsk direct standards transparency established therapeutic interest working strong global principles patient associations glaxosmithkline part gsks commitment working ethically always comply local patient groups employees involved receive lawsgovernance formal training global principles work contribution society within framework set standard operating procedures addition employees access believe business adds social patient advocacy resource intranet site economic values society contribution products make healthcare uk gsks advocacy work governed jobs wealth generate association british pharmaceutical industry abpi code practice states must contribution healthcare written agreement company medicines vaccines enable people live patient group companies must publish longer enjoy better quality life list patient groups fund healthcare expensive especially patients list uk patient groups receiving funding need make frequent visits doctor spend gsk gone towards greater time hospital example us every transparency extended list include spent healthcare goes treating people patient groups europethat receive funding chronic diseases healthcare costs also likely gsk given full details funding rise many countries population europe gsk developed standard operating ages vaccines medicines reduce burden procedure sop working patient groups healthcare systems preventing diseases enabling initiative extended gsk people chronic diseases work helping regions sop covers variety areas patients control symptoms make fewer concerning gsks work patient groups states visits hospital gsk seek patient groups gsk contributes healthcare three ways endorsement medicine disease prevention provide percent patient groups overall funding become effective intervention medicines treat percent funding vast majority diseases instances actual percentage much lower innovation investment rd discover new additionally activities accompanied medicines vaccines meet future written agreement healthcare needs gsk working many pharmaceutical company representative bodies encourage industrywide transparent ethical approaches working patient groups gsk corporate responsibility report corporate responsibility report disease prevention preventing disease better potential patient community investment support several major avoids illness pain suffering better disease prevention programmes developing society reduces healthcare costs countries community investment support disease prevention efforts several ways include vaccines global alliance plans completely make vaccines protect crippling eliminate lf disfiguring disease one fatal diseases including hepatitis b diphtheria worlds leading causes permanent seasonal flu polio tetanus whooping cough disability see community investment currently supply vaccines diseases global immunisation efforts led phase programme reduce diarrhoea eradication smallpox potential eradication related disease encouraging school children polio estimated save lives developing countries wash hands three million people worldwide year see community investment vaccination longer term benefit intervention cost effective treating people key pharmaceutical products target serious become sick also reduce healthcare costs diseases including preventing disease outbreaks asthma chronic obstructive pulmonary reducing need expensive treatments disease hospitalisations epilepsy depression diseases reducing permanent disabilities long central nervous system term effects disease hivaids herpes viral diseases preventing loss productivity illness infections gsk vaccines diabetes distributed billion vaccine doses countries developed cancer developing world average million doses heart disease cardiovascular diseases day invested million vaccine research scientists working urogenital diseases vaccine research centres make major contribution healthcare make vaccines available developing several ways countries innovative tiered pricing prolonging life gsk pioneer treatments model percent billion hivaids antiretrovirals arvs vaccines produced went developing combivirhelp patients control effects world currently researching new vaccines hiv infection many years sell arvs diseases including several countries subsaharan africa notfor particularly relevant developing countries see profit prices see access medicines access medicinespage preventing complications many diseases patient education support patient education diabetes progressive patients dont disease prevention initiatives include receive right treatment suffer working patient advocacy groups severe side effects every day us diabetes producing patient information leaflets medicine cause estimated amputations packs doctors surgeries publishing around cases blindness people information disease preventionon website experiencing kidney failure avandia antismoking estimated around five diabetes treatment helps patients control million people die prematurely year result symptoms delays progression smoking makes smoking cessation one disease prevents complications avandia effective ways improve health gsks used seven million nicotine replacement therapy brands people worldwide nicoderm nicorette helped improving quality life many five million smokers quit since making medicines asthma significant contribution public health diabetes help patients chronic diseases live full productive lives gsk preventative treatments asthma seretideadvair control symptoms asthma prevent asthma attacks curing infection produce antibiotics treat respiratory tract infections donated antibiotics help relief efforts disaster areas see communityon gsk corporate responsibility report corporate responsibility report value uk economy innovation british pharma despite revolutionary advances healthcare health organization predicted copd group comprising two still many diseases cure third leading cause death ukbased companies gsk treatments could improved gsk study involve patients astrazeneca commissioned continued research innovation essential three years identify relevant markers report office health economics ohe indepen may help predict disease progression believe rd new medicines dent research organisation important element corporate responsibility many diseases caused genetic factors companies value uk economy company gsk invested billion makes difficult cure prevent employed people rd research bodys immune system also report used concept enable us develop safer effective economic rent net pipeline additional income wealth prescription medicines vaccines targeted vaccines protect greater brought uk number diseases clinical development current projects include company excess income research asthma cancer depression diabetes economic value would generated labour capital put epilepsy heart disease hivaids influenza irritable contribute countries operate next best alternative use bowel syndrome osteoporosis schizophrenia creating wealth employment paying stroke tb taxes purchasing products services well ohe stated estimated net economic rent direct financial contributions products expect launch five major new vaccines within earned many enterprises also contribute indirectly economic growth next five years economy expected preventing treating disease close zero ie yield human papilloma virus vaccine preventing much economic value detailed financial information available cervical cancer significantly annual report however key figures next best alternative uses usa launch vaccine rotavirus global business capital labour employ induced gastroenteritis strengthening global figures gsks astrazenecas rotavirus vaccine uptake europe economic rent manufact international markets sales uring rd activities uk estimated vaccine pneumococcal disease rd investment least billion annually nontypeable haemophilus influenzae possibly much higher infections causing otitis media payments gsk contributes approximately employees percent figure number vaccines seasonal read copy avian flu based gsks unique expertise suppliers na na report background section adjuvant technology including new government taxation website generation adjuvanted seasonal flu vaccine studies also ranked elderly people community investment gsks value uk economy vaccine combinations meningitis na available highly uk government department experts predicting may major flu trade industry dti pandemic next decade caused hn value added scoreboard lists strain bird flu gsk actively preparing companies making largest potential crisis pivotal clinical trial gsks new human rights contributions value added generation hn influenza vaccine carried uk europe gsk belgium shown low doses human rights broad subject relevant ranked thin uk thin europe highest pharma antigen g combined gsks novel gsk number different contexts ceutical company value adjuvant system elicited strong seroprotective committed upholding human rights added calculated response gsks vaccine also believed sphere influence greater control billion per potential offer protection drifted employee human rights operations variants hn virus could used part also influence human rights among suppliers investment rd stimulates proactive prepandemic vaccination campaign wider society economic growth gsk ranked addition also increased production relenza thin uk dtis rd treatment influenza full review gsks sphere influence scoreboard ranks top pipeline please see annual report several reasons take human rights global companies value rd investment extensive rd programme diseases seriously highest ranked uk company disproportionately affecting developing countries achieving high standards human rights see wwwdtigovukinnovation believe gsk company researching supports reputation goal new vaccines treatments hivaids tb operational excellence malaria world health organizations three helps us get best employees priority diseases working suppliers match research causes disease standards help ensure smooth well researching potential new medicines operation supplier contracts therefore also invest research increase understanding reliable supply high quality products human body causes disease supports good relationships example launched eclipse non communities near sites drug study improve understanding chronic obstructive pulmonary disease copd world gsk corporate responsibility report corporate responsibility report approach human rights guided un wide variety biological materials used universal declaration human rights oecd biomedical research include human guidelines multinational enterprises core materials nonhuman materials found humans labour standards set international labour bacteria viruses animals plants organisation obtained various sources sometimes indigenous unique country employees community commonly cultivated direct employees well educated bred staple commercial products obtained skilled people risk human rights issues ordinary commercial channels occurring relatively low believe employment standards issues diversity today gsks pharmaceutical research equal opportunities health safety provide based screening large numbers synthetic adequate safeguards human rights chemical compounds rather natural resources employees information see employment currently access benefit practiceson sharing agreements place however gsk undertake development work using indigenous suppliers genetic resources associated traditional expect suppliers contractors business knowledge arising gsk natural product partners meet standards human collection programmes access resources rights gsk recognise suppliers would obtained accordance local laws may seek influence suppliers contracts would negotiated required adopt high standards human rights adding appropriate authority would thereby ensure human rights clauses contracts clear benefit returned country auditing suppliers information see supply origin example royalties share chainon net profits see policy biodiversity communities society human rights relevant relationships improving healthcare particularly developing wider community stakeholders world one greatest challenges world examples faces gsk committed playing part countries poor human rights records improving access medicines contribute stakeholders concerned healthcare developing world presence countries poor human research new treatments vaccines rights record sudan north korea making medicines available affordable burma respect concerns preferential prices negotiating voluntary licences medicines vaccines needed local generic manufacturers populations products need registered community investment information see governments sold access medicineson community almost always requires interaction aspect investmenton government believe along un engage governments multilateral agencies people denied access medicines ngos help improve access medicines regime operating country developed seven point plan use see un document advocacy efforts information see local communities seek reduce environmental impacts sites operate safely foster good relationships local communities indigenous material traditional knowledge one worlds leading pharmaceutical companies gsk fully supports convention biological diversitys role providing framework conservation biological diversity sustainable use components respect traditional knowledge also support cbd objective provide fair equitable sharing benefits arising use genetic resources gsk corporate responsibility report corporate responsibility report access medicines millions poor people developed developing countries struggle get medicines need supporting efforts improve access healthcare workers aids pandemic making medicines section explains situation even worse depriving communities greatest asset healthy productive people contribution developing world tackling crisis complex challenge requiring research preferential pricing partnerships visionary leadership poverty huge barrier voluntary licences community investment progress significant political extra resources important public health initiatives needed aid development build healthcare infrastructure disease programmes need well pricing arrangements discount cards coordinated ensure health systems middleincome countries whole benefit patient assistance programs discount cards believe responsibility help uninsured patients us governments intergovernmental agencies believe response right supplemented work ngos deliver thing makes good business sense healthcare countries however companies adapt business practices pharmaceutical industry play significant role address challenges leaders supporting efforts future competitive market talented make important contribution people also helps us attract retain best people research development diseases disproportionately affecting developing differential pricing increases affordability patients countries believe gsk currently whilst maintaining support intellectual company researching new vaccines property system intellectual property rights treatments hivaids tb malaria essential pharmaceutical industry world health organizations three priority without would able invest diseases much research conducted rd new medicines vaccines public private partnerships finding innovative ways help poor people preferential pricing specially reduced prices developed developing countries access antiretrovirals arvs antimalarials medicines addressing ethical reputational vaccines shipped commercial imperatives reasons million combivirand epivirtablets access medicines strategic business driver forprofit prices treatment hivaids gsk poorest countries world also support underserved communities seeking innovative partnerships gsk worldwide donations funding granted eight voluntary licences practical support see community investment manufacture supply generic versions developing world leading arvs treating hivaids africa poverty caused healthcare crisis many parts active partnerships roll developing world millions people back malaria stop tb access reliable food clean water never community investment public health mind adequate healthcare despite unprecedented initiatives partnerships foster effective resources made available public health healthcare including major programmes many governments unable fund clinics tackle lymphatic filariasis malaria hivaids staff needed deliver basic healthcare diarrhoeal disease see community investment world bank estimates per person per research development year needed provide basic health research development rd new drugs services yet average spend subsaharan vaccines essential element improving africa african region health developing world still suffers percent global burden effective treatments widespread life disease percent worlds threatening diseases many existing treatments health workers migration african health workers diseases malaria becoming less effective wealthier markets exacerbating situation due drug resistance globally shortage well million gsk corporate responsibility report corporate responsibility report hivaids affects developed diseases developing world ddw access healthcare whose developing countries commercial market includes ddw drug discovery centre tres responsibility new treatments encourages investment cantos rd site spain scientists access healthcare developing world remains required rd gsk industry leader based clinical development experts complex issue believe research hivaids treatment prevention uk us ddw projects prioritised according holistic approach social public health benefits rather embracing prevention however many diseases disproportionately commercial returns similar group exists treatment work affect developing world lack resources vaccines organisation based belgium stakeholders role play healthcare means often viable pharmaceutical companies must commercial market new treatments public total gsk conducting rd diseases make medicines affordable private partnerships ppps helping address particular relevance developing world developing countries problem includes clinical programmes medicines invest research diseases vaccines diseases seven developing world new gsk collaborates several ppps including projects diseases disproportionately treatments urgently needed medicines malaria venture mmv global alliance tb drug development tb alliance affect developing countries wealthy nations must give summarised welcome new funding coming aeras global tb vaccine foundation aeras global fund malaria vaccine initiative mvi international fight aids tb malaria aids vaccine initiative iavi gates foundation pepfar hivaids malaria leishmaniasis dengue fever hepatitis c us presidents emergency plan gsk created dedicated group hepatitis e n meningitis cervical cancer tb chlamydia aids relief others pharmaceutical rd organisation focus pneumococcal disease funds still inadequate resources needed fund research purchase medicines development pipeline end diseases relevant developing world discourage export trained healthcare workers focus preclinical activity phase phase ii phase iii marketed developing countries developing countries must show hiv integrase inhibitor retrovir epivir genuine political commitment hiv entry inhibitor combivirziagen addressing stigma removing nnrti trizivir agenerase import tariffs prioritising kivexatelzir healthcare national budgets middleincome countries must vaccines hiv malaria synflorix rotarix accept responsibilities malaria hiv dna p falciparum pneumococcus rotavirus seek lowest prices p vivax antiviral tb disease havrix offered worlds poorest hiv vaccine hepatitis e cervarix hepatitis countries chlamydia dengue fever cervical cancer engerixb developed seven nmeningitis hepatitis b point planfor sustainable combinations twinrix approach improving hep ab healthcare developing infanrixtritanrix world use dpt family advocacy efforts diptheriatetanus included pertussis boostrix submissions uk department international dtp acellular developments dfid polio sabin consultations white polio paper eliminating world priorix poverty making governance measlesmumps work poor also rubella health strategy typherix typhoid hiberix submissions g haemophilus influenzae governments ahead st petersburg summit type b mencevaxacw facetoface meetings meningitis hilary benn uk international development secretary un malaria tefenoquine cda lapdaphalfan secretary general kofiannan malarone uk government officials white house officials eu tb officials ngo representatives sitamaquine zentel hepatitis c visceral deworming agent interactions unaids leishmaniasis pentostam unitaid new visceral leishmaniasis international drug purchase banocide facility world health lymphatic filariasis organization gsk india detailed information product pipeline found annual report gsk corporate responsibility report corporate responsibility report whats different rd progress hivaids medicines developing vaccines world malaria gsk leader global effort develop gsk scientists working vaccines aids vaccine involved aids treatment projects diseases gsk working malaria vaccine vaccine research two decades disproportionately affecting developing countries make years clinical trials malaria vaccine today pursuing four separate vaccine access medicines priority children showed vaccine remained technologies successful aids vaccine might need right start rd efficacious months reducing severe combine several approaches process malaria percent children several years researching new clinical investigation needed results gsk institut pasteur working together treatments produce target indicate potential help save millions develop aids vaccine fusing genes product profile tpp outlining childrens lives additional phase ii clinical hiv virus onto existing measles vaccine characteristics trials vaccine initiated mozambique project supported euro million looking new molecule kenya tanzania gabon ghana million grant european union well safety efficacy tpp new ddw treatment supported grant malaria vaccine part public private partnership emphasises factors initiative pathfunded bill melinda international aids vaccine initiative iavi gates foundation evaluate develop aids vaccine using nonhuman primate heat humidity resistance product vaccine different settings younger adenovirus vector technology collaboration must able survive children trials successful partners first ever aids vaccine research iavi hot climate initiate largescale phase iii clinical trial major vaccine company facilitate may refrigeration results continue positive vaccine could research vaccines types hiv facilities submitted regulatory approval early circulate predominantly africa ease use must easy use settings treatments gsk biologicals also inhouse aids vaccine limited healthcare working closely medicines development project using companys prop facilities example malaria venture subsidises scientists rietary adjuvant system technology two phase aday tablets tres cantos facility world health clinical trials conducted vaccine taken home organization academic partners united states partnership us preferable injectable develop cda affordable fixeddose artemisinin national institutes healths hiv vaccine trials medicine must administered hospital combination treatment drugresistant malaria network belgium ghent clinic africa phase iii clinical trials initiated university trials completed several sites across africa additional phase iii respectively demonstrated vaccine safe affordability price one important study planned involving infants produces strong immune response third factors look ages three months one year aim phase trial hivinfected volunteers molecules formulations submit cda regulatory approval early initiated late collaboration straightforward march identified lead candidate partners aids research center massachusetts manufacture therefore inexpensive produce gw take forward development general hospital boston results pyridones project along backup currently analysed followup approach candidate gw drugs explores similar strategy using new antigen potential highly active drugresistant named f phase clinical trial f vaccine strains malaria show none toxicity candidate scheduled begin near future issues affected previous candidate class belgium significant chemical pharmaceutical develop fourth approach aims develop improved ment undertaken antimalarial drug adjuvanted envelope env protein vaccine able gsk ntert butyl isoquine plan produce neutralising antibodies provide start clinical studies humans partner lasting protection infection hiv funding becomes available drug relatively approach currently preclinical evaluation straightforward synthesise manufacture treatments therefore potential relatively december discontinued clinical inexpensive development brecanavir protease inhibitor clinical data tafenoquine new antimalarial patients multidrug resistant hiv infection developed partnership us military unable develop oral dosage shown tafenoquinecontaining formulation could consistently deliver combination regimen may work faster existing correct dosage brecanavir patient therapies treatment p vivaxmalaria scientists working new hiv medicines may also help address concerns emerging several different drug classes integrase inhibitor resistance existing treatments discovery programme active lead discussions regarding funding additional candidate c developed development work treatment p vivax partnership shionogi currently phase ii malaria plan proceed clinical development new hiv entry inhibitor non development nucleoside reverse transcriptase inhibitor nnrti candidates entering pipeline gsk corporate responsibility report corporate responsibility report experts unicef stated access partnership stellenbosch university south appropriate arv tablets opposed arv africa gsk supporting grant applications fund liquid formulations would facilitate treatment programme identify biomarkers people children old enough able swallow tablets may respond specific treatments developing scored tablets key arvs biomarkers used predict whether epivir ziagen combivir broken patients respond quickly treatment tb two smaller doses suitable treatment likely recur children simplify treatment help rotavirus physicians carers administer right dose rotavirus infection leading cause severe efficiently safely children expect diarrhoea vomiting gastroenteritis children submit scored tablets registration two kills around children want continue play important role year one child every minute mostly developing treatment hiv children support countries vaccine rotarix prevention four paediatric clinical studies involving rotavirus induced gastroenteritis launched children five resourcepoor countries mexico january approved countries registered provide arvs international hiv registrations collaborative research trial programme support developing world vaccine part clinical studies run third parties currently national immunisation programmes new supporting clinical studies involving born babies eight developing countries including patients studies taking place sub brazil el salvador mexico panama venezuela saharan africa include eight studies distributed million doses since launch prevention mothertochild transmission one early gsk received prequalification status prophylactic properties four studies children rotavirus vaccine world health mentioned four hivtb coinfection organization required un four adult treatment strategies studies organisations gaviformerly known intended advance knowledge use global alliance vaccines immunisation arvs resourcepoor settings also help purchase vaccine timely increase access arvs complemented decision gavi late tuberculosis tb provide funding support introduction tb kills two million people year leading rotavirus vaccines developing countries cause death among people aids cervical cancer developing world new drugs tb cervical cancer common cause cancer discovered years deaths women developing world current vaccines published data suggest cervarix vaccine gsk aeras global tb vaccine could reduce percent womans lifetime risk foundationare developing gsks tb candidate developing cervical cancer applied vaccine earlystage clinical trials us registration vaccine europe well belgium showed vaccine safe well countries international region tolerated produces strong immune response track file regulatory approval began additional trials involving adults us april committed previously infected tb vaccinated making cervarixwidely available make bacillus calmettegurin bcg plan conduct available lowincome countries preferential studies africa locations test prices gsks tiered pricing model safety efficacy vaccine candidate vaccines populations highly affected tb conducting clinical studies use treatments vaccine low income settings launched joint drug discovery leishmaniasis partnership global alliance tb drug sitamaquine potential new onceaday oral developmenttb alliance tb alliance aims treatment visceral leishmaniasis disease accelerate development affordable drugs affects half million people year developing shorten treatment effective world usually fatal untreated gsk multidrugresistant strains tb compounds providing funding project new screened ensure taken treatment visceral leishmaniasis urgently hiv treatments tb alliance supporting needed since current medicines either fulltime scientists working exclusively tb impractical becoming ineffective due drug drug programme tres cantos gsk contributing resistance simply unaffordable sitamaquine matching number staff remaining shown good efficacy phase ii trials trials overhead costs around million compounds also suggest shorter treatment period tested antitb activity achieved perhaps half four weeks four preclinical tb projects underway needed current treatments low cost suggests sitamaquine could first truly accessible treatment visceral leishmaniasis affects poorest poor gsk corporate responsibility report corporate responsibility report public private partnerships ppps preferential pricing ppp ppp companies gsk poverty lack political insufficient medical supply licencees supplied provide rd technology infrastructure hospitals clinics health workers million tablets versions epivirand manufacturing distribution biggest barriers accessing healthcare combivirto africa expertise academic institutions developing countries may also provide research continue look new customers disease area knowledge public affordability medicines also important nfp arvs countries regularly review sector partners governments two elements nfp prices however may well organisations licencees able produce firstline arvs lower gates foundation help fund ability governments patients pay development delivery costs costs increase share business medicines governments inter ensure medicines get governmental agencies must make significant massive scaleup treatment hivaids people need funds usually channelled additional financial resources available solve planned global community next five organisations problem years negotiating agreements contract medicines malaria manufacturers ensure capacity price medicines sold area venture contribute meeting demand gsk help address ppps needed published new treatment guidelines gsk wants invest research making arvs antimalarials available tackle diseases blight developing countries affordable prices patients hiv arv abacavir developing world however recommended firstline treatment option major commitment call preferential dilemma must may reduced nfp price abacavir pricing includes notforprofit nfp prices profitable sustain business containing arvs percent made two continue develop new worlds poorest countries discounted prices new arvs kivexaand telzir available nfp medicines business model wealthier developing middleincome countries prices work cases see prospect concerns pharmaceutical commercial return factors supply chain taxes companies enough register unfortunately lack resources tariffs distributor markups significantly essential medicines developing countries means limited market increase price medicines factors new treatments diseases prevents countries taking advantage control addressed disproportionately affect preferential pricing offers continue review governments developing countries ppp registration needs key arvs model business middleincome developing countries target developing countries ensure epivir public sector work together continue negotiate public sector prices case retrovirand combivirare available widely offers solution bycase basis improve affordability see necessary possible partnership work practice gsk vaccines also available preferential prices current focus also make abacavir drug discovery takes place use tiered pricing structure vaccines prices abacavircontaining arvs available dedicated diseases developing world little tenth locations prioritise efforts developing world discovery developed countries work greatest medical need particular centre tres cantos gsk multinational organisations unicef pepfar countries developing countries provides facilities meets running costs world health organization pan american significant hiv burden highquality gsk scientists tres health organisation governments non alternatives abacavir available cantos half governmental organisations provide appropriate product diversion notforprofit medicines subsidised partner affordable vaccines developing countries organisations medicines illegally shipped back sale wealthier includes basic polio vaccines well specially malaria venture mmv countries denies treatment patients poorer developed combination vaccines target several global alliance tb drug countries antidiversion measures include development tb alliance diseases billion vaccines access packs red rather white tablets shipped around percent went developing compounds move clinical combivir epivirtablets epivirsolution trizivir world lower previous years due development gsk provides retrovirsolution registered clinical regulatory timing significant tenders countries gsk first company manufacturing expertise progress receive positive opinion epivir combivir resources global shipped million tablets nfp combivirand red coloured tablets european medicines rd supply network partners help fund cost million tablets nfp epivirto developing evaluation agency emea via article running clinical trials address world compared million million regulatory procedure medicines intended issues access distribution tablets respectively use outside eu serve speed reduces costs registration red coloured tablets developing development gets new decrease expected primarily due countries products patients faster customers purchasing arvs generic research programmes manufacturers including licensed gsk overseen joint steering positive indication licensing policy committees representatives working gsk partners affect price last year generic manufacturers licensed new treatments gsk significantly increased importantly terms manufacturing capacity ability supply larger agreement quantities arvs lower prices welcome committed make new trend gives customers subsaharan africa treatments resulting ppps accessible developing greater choice contributes better security world affordable prices gsk corporate responsibility report corporate responsibility report report unled accelerating access initiative aai suggests september people living hivaids developing countries receiving treatment least one arv supplied seven pharmaceutical companies aai compared people treatment includes patients africa extending preferential pricing considering extending preferential prices africa wider range products however number commercial factors overall market environment must considered findings five country pilot study informing evaluation voluntary licensing partnerships gsk wants play part global response hivaids pandemic preferential pricing arrangements enable us supply highly discounted safe quality products long needed situations voluntary licences also help increase supply medicines voluntary licences vl enable local manufacturers produce sell generic versions products granted first vl negotiated eight licencing agreements arvs africa includes new licence agreed south africa company vls cover individual countries trade blocks whilst others cover subsaharan africa vls universal solution hivaids specific response particular set circumstances decision grant vl depends number factors including severity hivaids epidemic country local healthcare provision economic manufacturing environment selecting appropriate licensee key need sure manufacturer able provide longterm supply good quality medicines implement safeguards prevent diversion medicines wealthier markets gsk corporate responsibility report noillim stelbat fo rebmun notforprofit prices supply preferentially priced much discussion use summary combivirand epivirtablets compulsory licences intellectual property rights taken away rights holders medicines compulsory licenses one flexibilities hivaids arvs world trade organisations trips agreement malaria treatments gsk licencees intellectual property gsk believes widespread customers use compulsory licences undermine public sector customers intellectual property framework counter forprofit organisations productive long term rd new eligible countries private employers subsaharan africa treatments especially commercial markets provide treatment non exist hivaids depends protection insured staff intellectual property countries least developed countries subsaharan africa well countries eligible global fund pepfar middleincome countries projects countries total see eligibility notfor middleincome countries economically profit prices background developed often healthcare demands section website outstrip available resources challenges details made worse growing aids epidemic cost many middleincome countries combivir leading arv available day nfp afford supply products low prices prices also include delivery worlds poorest countries still make insurance costs adequate return wealthier markets much nevertheless recognise many middle nfp prices applicable income countries need assistance orders size dependent large order negotiate preferential pricing arrangements quantities middleincome countries casebycase basis done bilaterally dialogue long nfp prices sustainable governments believe best approach make profit since disease burden resources available cover address vary significantly country country manufacturing distribution also within countries arrangements costs therefore continue combine viable sustainable commercial return supply longterm gsk improved affordability healthcare systems concerned several developed countries also introducing discount cards senior citizens see developed world activity russia announced agreement supply arvs russian government discounted prices first direct federal purchase antiretroviral medicines russia gsk supplied treatment packs russian government hiv medicines combivir epivirand ziagen dispensed hospital centres across country agreement contribute russian governments target reaching patients end target doubled china september signed voluntary licence simcere chinese manufacturer granting right manufacture sell zanamivir relenza containing products china indonesia thailand vietnam ldcs relenzais anti viral help treat influenza half human cases flu caused hn virus occurred asiapacific regioncorporate responsibility report intellectual property rights india india developed large generics industry partly significant reduction last year result national legislation permit reflects introduction new drug benefit patent protection pharmaceutical products part us medicare programme known comply wto trade related medicare part prior medicare patients aspects intellectual property rights trips prescription coverage medicines agreement india introduced legislation allowed patient enrolled medicare part patenting pharmaceutical products plan became ineligible existing patient context access medicines debate assistance programmes bridge access argue obligation india result commitment access however still recognise end provision cheap generics even drug coverage patients undermine future availability affordable may still need assistance new programme gsk innovative products accessprovides extra help low income senior disabled medicare part patients need gsk believes intellectual property getting medicines programme allows protection provisions set trips vital spend pocket development medicines meet unmet medical prescription medicines whose incomes needs around world robust ip system percent percent essential encourage researchbased companies percent oncology products federal undertake risky hugely expensive rd poverty level apply eligible obtain gsk discover new better medicines vaccines medicine free remainder see generic medicines already wwwgskaccesscomfor information market india affected expect new programme increase number introduction patent protection continue patients assistance programmes available india elsewhere way today also believe public health safeguards trips agreement january gsk nine pharma prevent access problems future ceutical companies created discount savings programme improve access medicines root cause developing countries inability uninsured americans eligible address healthcare problems lie medicare together rx accesscard provides patenting system lack funding savings percent lack political inadequate healthcare medicines approximately million people infrastructure none factors affected around percent people us without intellectual property rights full implementation prescription insurance eligible enroll trips india elsewhere participating companies enrolled people received million day prescriptions saving million based wac gsk provided discounts million developed world patients day prescriptions access medicines issue orange cardsin middle income countries developing world even developed countries orange cardin ukraine gives asthma patients afford medicines chronic obstructive pulmonary disease patients need particular problem us average discount many people health insurance gsk percent popular presentations developed patient assistance programs gsks seretide asthma medicine asthma patients discount savings card us help patients age suffer disabilities affected without insurance chernobyl nuclear disaster also eligible also introducing discount savings cards eligibility assessed patients doctor several middleincome countries enable patients receive medicine participating qualifying patients obtain prescription medicines pharmacies hotline number set discount price help patients find nearest pharmacy orange card discounts totalled programmes us patient assistance programs provide prescription medicines lowincome uninsured patients free lithuania orange card gives senior citizens minimal cost gsk operates several disabled average discount percent programmes including commitment access patient copayment gsk prescription covers cancer treatments bridges medicines far patients access covers medicines applied orange card patients patients registered one phone pharmacies percent pharmacies call patient advocate receive medicine lithuania registered participate local pharmacy mail order patients received discounts worth patients received gsk medicines worth million programmes compared million value medicines calculated using wholesale acquisition cost wac gsk corporate responsibility report corporate responsibility report gsks orange cardin bulgaria provides lowincome patients discount gsk medicines treat chronic diseases asthma chronic obstructive pulmonary disease diabetes broadened scope orange cardin response changes bulgarian reimbursement system meant patients chronic diseases could longer access state assistance currently prescribed medicines orange cardprovides direct benefits form subsidy patients suffering three important chronic diseases bulgaria asthma diabetes benign prostate hyperplasia gsk investment orange cardin bulgaria euro million million summary gsk discount programmes country gsk programme number patients value benefit patients us patient assistance programs free minimal cost medicines lowincome received million uninsured patients prescriptions million us together rx access discounts lowincome uninsured patients received million joint industry programme prescriptions million bulgaria orange card discounts lowincome euro million patients chronic diseases approx million lithuania orange card discounts senior citizens disabled people ukraine orange card discounts asthma copd medicine patients available gsk corporate responsibility report corporate responsibility report research research development rd new medicines vaccines core business makes significant contribution society product pipeline new medicines vaccines brought animal research gsks rd pipeline includes huge benefits health quality life potential new treatments animal research testing essential millions people last years vaccines many serious component understanding disease debilitating conditions continued rd remains important ever evaluating safety effectiveness new vaccines including still many serious debilitating life prescription overthecounter medicines threatening illnesses effective alzheimers disease treatments treatments could safety regulations require us test new asthma significantly improved medicines animals tested atherosclerosis clinical trials using humans vaccines goal build best product pipeline cancer industry invested billion tested animals time new batch produced depression billion employed people diabetes rd gsk animal research laboratories europe asia us animal research conducted heart disease research aims address unmet medical needs external contractors behalf pipeline includes compounds potential hivaids represents additional percent animals make major contribution healthcare influenza estimate animal research accounts around developing countries see access medicines percent gsk research expenditure malaria throughout rd process seek views rheumatoid arthritis patients inform research focusing patient around percent animals used gsk needs drives innovation brings commercial rodents rats mice guinea pigs rabbits tb success remaining percent includes fish ferrets pigs dogs cats primates recognise biomedical pharmaceutical research raises ethical concerns use animals used gsk new technologies objective reporting clinical trial results committed attaining mouse high ethical scientific standards rd work section explains approach rat animal research efforts reduce guinea pig refine replace animal testing rodent conduct clinical trials ensure rabbit gsk sponsored clinical trials carried high ethical standards irrespective conducted ultimately gsk would like see important training auditing clinical trials benefits research achieved without use train gsk employees involved clinical trials experimentation potential cause check trials carried pain distress animals believe good clinical practice gcp standards achieved foreseeable future therefore gsk committed rs reduction clinical trial information results refinement replacement animals research publicly disclose trial information results achieving high standards animal welfare journal articles gsk clinical trial goal use animals scientifically register public databases necessary use scientifically feasible patient safety monitor safety minimise pain distress medicines approach continues impact background information approach new small increase absolute numbers technologies including pharmacogenetic animals used baseline however researchand use transgenic animals growth rd activity continues greatly available website exceed increase animal use started estimating external animal use recorded external animal use representing total animal use laboratoriesthis change may represent rise also improvement reporting data diverse external collaborations use baseline comparison first year able collect reliable datathe increased use due mice usedespecially vaccines testing gsk corporate responsibility report corporate responsibility report change rd activity compared change number animals used gsk research laboratories rd activity animal used data include animal research conducted external contractors behalfrd activity combines rd budget vaccine salesthe two main drivers animal usevaccine sales included since vaccines tested animals time new batch produced gsk corporate responsibility report ecnis egnahc change rd activity compared change number animals used gsk research laboratories year animals used rd activity corporate responsibility report recent gsk advances rs regulation internal controls replaced wildcaught animal research laboratories comply animal welfare awards recognise employees primates used safety national laws animal welfare regulators carry made outstanding advances testing oral polio vaccines regular unannounced inspections sites implementing rs research team primates bred looking smoking cessation products received captivity also proposed research testing using animals reduced number award reducing percent number considered gsk ethical review committees gsk primates used rats used studies addictive properties laboratories external laboratories purpose percent smoking products compared conducting research behalf must follow progressing replacement code practice animal research sharing best practice primates used includes best practice standards animal care fund uk national centre rs safety testing oral polio use ncrs prize recognises best new vaccines genetically techniques implementing rs modified mice date independent accreditation association prize money technique achieve remains subject accreditation assessment laboratory regulatory approval animal care aaalac international one way reduced number mice subjected invasive procedure used bacterial disease replaced rats used laboratories demonstrate meet best research supply brain tissue practice standards ten animal laboratories rat stem cell culture accredited aaalac located together industry partners association continuously produces belgium italy spain uk us british pharmaceutical industry funding cells without need accreditation covers percent threeyear job post ncrs encourage use animals avoiding use rats year animals used gskowned laboratories sharing best practice aim achieve aaalac accreditation increased donated internal guide refining number macaque laboratories collection blood samples laboratory monkeys housed pairs expand business new markets animals available free ncrs allowing social increase vaccine production work website interaction improves animal wellbeing external partners develop new medicines involved many initiatives also conduct animal research testing introduced use encourage research rs stimulate countries worldwide assessing impact catheters automated sharing best practice animal research blood collection systems changes programme animal gsk significantly reduce research updated policy number rats used review studies sponsor externally took part working groups run ncrs pharmacokinetic studies replacing reducing use primates studies absorption three rs research distribution metabolism implementing rs commits us excretion medicines supported universities federation new approach replacing animal studies alternative animal welfares projects improve housing significantly reduces animal methods wherever possible husbandry laboratory animals use percent reducingthe number animals used commonly used type participated european rspca frame study study industry initiative reduce use dogs information refiningstudies minimise pain maximise safety testing implement rs available information obtained animal website supported national academys institute example currently replacing use laboratory animal research johns primates mice vaccine batch testing beyond hopkins center alternatives animal looking ways use advances testing us quality control processes vaccine production advocacy change testing requirements eventually work stakeholders encourage reduction necessary test batch vaccines refinement replacement animal research animals testing training awareness joined european partnership alternatives provide training rs staff animal testing collaboration involved care use animals publish european commission major quarterly news bulletins rs raise companies seven industry sectors awarness worked range stakeholders ensure ethical review committees gsk scientists impact animals reach chemicals statisticians senior managers animal technicians initiative addressed believe veterinarians encourages rs culture gsk existing data records longterm human seminars recommended practice exposure records modern techniques guidelines scientific procedures animal use animals provide welfare data required product testing many established products use time closed laboratory japanacquired laboratories croatia canada established gskmanaged laboratories singapore usgiving current total gsk laboratories use animals gsk corporate responsibility report corporate responsibility report gave evidence uk academy medical conduct clinical policy payments sciences study use nonhuman healthcare practitioners trials primates research confirmed institutions conducting gsk sponsored gsksupported strong justification essential use safety effectiveness new medicines clinical studies however concluded vaccines must evaluated human clinical trials clinical trial investigators means address clearly defined approved marketing selected solely questions particular biological medical regulators give approval trials qualifications conduct importance strong scientific demonstrate product safe effective clinical research history moral case carefully regulated use benefits outweigh risks potential using gsk products taken account nonhuman primates side effects payments practitioners participated study animal pain new product typically tested three reflect fair market value distress research study conducted stages clinical trials involve healthy work performed laboratory animal science association individuals patients relevant disease payments offered animal procedures committee assessed made could influence projects clinical whether severity pain distress could judgement whether development retrospectively reported study found enrol maintain research institutions already keep standards clinical trials participant clinical study record pain distress experienced gsk clinical trials wherever carried individual animals concluded making conducted according good clinical information public would useful would practice gcp guidelines developed increase transparency study looking international conference harmonisation ich ways could done without introducing principles contained world medical excessive bureaucracy association declaration helsinki ethical principles medical research involving communicating approach human subjects people hold strong views animal research testing believe important explain ich guidelines provide internationally need animal research testing open accepted ethical scientific quality standard designing conducting recording reporting trials cover issues selection laboratories host visits schools colleges training trial investigators gaining informed animal welfare organisations others consent trial participants monitoring made visits uk schools hosted quality assurance site visits us host regular science literacy teacher workshops animal research trial protocols plan clinical trial pennsylvania north carolina associations conducted reviewed external regulatory biomedical research teachers agencies relevant countries required taken part since protocols considered relevant ethical review committees cover sites engage regularly animal welfare studies take place organisations investors well contributing debate media article ethics review committee composed lay animal research uk times thapril people medical professionals scientists followed visit gsk uk animal laboratory assess whether trial justified whether designed conducted according sustainability corporate responsibility appropriate ethical standards ethics committees consultancy thinktank benchmarked power reject stop clinical trial reporting animal research concluded overall comprehensive discussion safety data routinely collected throughout animals research industrys reporting development programmes reported animal welfare concerns integrated regulators line applicable regulations data gsks operations contracting also reviewed gsk ongoing basis safety signals events necessarily caused protest treatment require exploration gsk accept right lawful protest animal global safety board gsb led chief research part free society condemn medical officer composed senior physicians use violence intimidation scientists gsb oversees safety opposed animal use public stance investigational marketed compounds extremism complimented approving administration investigational media uk guardian thmay uk compounds humans defining doses prime minister uk sunday telegraph th may duration treatment considered safe robustness openness welcome gsk global safety board responsible apparent shift uk away extremism approval pivotal protocols pivotal trials debate passage new legislation provide primary data regulatory animal extremism united states approval based internal assessment issues related patient safety arise product development programme marketed gsk corporate responsibility report corporate responsibility report audit clinical trials ensure conducted training auditing appropriate standards see training clinical trials auditing clinical trials provide training ensure clinical trials clinical trials outside western europe performed high ethical quality standards north america audit conduct clinical trials ensure clinical trials take place western europe carried according study protocol gsk north america gsk starting perform standard operating procedures sops good trials regions central eastern europe clinical practice gcp current regulatory directives south africa latin america parts asia laws guidelines ethical considerations seek conduct clinical trials declaration helsinki population relevant scientific employees involved designing conducting question results monitoring gsksponsored trials trained gcp generalised broader populations training mandatory employees must completed required training starting qualified investigators capable changing jobs carrying research training activities related people qualify participation gcp training activity represents research successful completion elearning module research carried quickly instructorled course related gcp one efficiently possible employees contractors gsksponsored clinical trials conducted keep detailed training records ethical standards irrespective routinely requested regulatory authorities location studies meet international national undertaking inspection assess competence regulatory legislative requirements employees undertaking clinical trials conducted accordance principles gsks internal audit department audits gsk systems good clinical practice gcp standards processes involved conduct trials principles contained world medical well auditing external clinical research association declaration helsinki ethical organisations investigators performing clinical principles medical research involving human research behalf risk management subjects gsks policies approach used determine trials gsk committed investing rd diseases audited risk factors evaluated include disproportionately affecting developing countries complexity study patient population see access medicines compounds must location study previous audit history usually tested clinical trials developing unusual findings conduct study countries disease prevalent audits conducted medicine relevant local population audits investigator sites conducting gsk leastdeveloped countries additional sponsored trials represents approximately safeguards may needed example percent investigator sites participating cultures still complying normal ethical pivotal clinical trials legal requirements additional steps taken match objectives informed consent local audits internal gsk systems processes culture example local leaders andor family used managing clinical trials data members may need involved consent audits clinical research organisations process carrying clinical trials gsks behalf read position clinical trials audits gsk local operating companies developing worldin background section including medical departments managing website clinical research countries cause audits conducted response suspected irregularities six investigators reported regulatory agencies audit results reported quarterly rd risk management compliance board annually gsk audit committee concerns issues identified audits fully investigated appropriate action taken may include retraining severe cases dismissal individuals concerned well development new training programmes procedures prevent reoccurrence trial data may also reanalysed gsk corporate responsibility report corporate responsibility report inspections investigators clinical research gsk follows phrma principles organisations independent ethics committees conduct clinical trials institutional review boards sponsors clinical communication clinical trial resultsand trials also carried regulatory authorities committed timely communication results ensure safety trial participants quality products approved marketing wherever data trials conducted according possible publish trial results peerreviewed gcp scientific medical journals conference inspections gsk investigators used gsk abstracts proceedings used conduct clinical studies research healthcare communities obtain latest information treatments gsk guarantee publication methods since discretion journal clinical trial information editors conference organisers reason results launched gsk online clinical trial register supplement prescribing information make results clinical trials widely publications scientific literature available healthcare practitioners others register contains results protocol use evaluate use medicines also information gsksponsored trials marketed publicly disclose information ongoing trials medicines also provides references publications ongoing clinical trials appeared medical journals anyone publicly available internetbased registration use internet access register ongoing clinical trials provide stimulus activity increased participation clinical research also end clinical trial provides important reference point interested summaries gsk clinical trial register parties track subsequent disclosure clinical httpctrgskcoukwelcomeasp includes trial results clinical trials major marketed products gsk legally required post summary protocol completed since formation information ongoing studies treatments gsk completed serious lifethreatening diseases conducted likely inform medical judgement us investigational new drug application continued populate register national institutes health website clinical trials relate marketed wwwclinicaltrialsgov medicines largely completed addition gsk posting protocol summaries clinical trials irrespective countries involved clinicaltrialsgov end protocol summaries actively recruiting clinical trials clinicaltrialsgov meet requirements postings set international committee medical journal editors non phase iii trials policy delay posting website certain data elements exceptional basis competitively sensitive clinical trial results pharmaceutical companies legally required disclose relevant data clinical trials appropriate regulatory authorities seeking approval new product approval sponsors continuing obligation provide regulatory authorities number summaries gsk clinical trials updated safety information clinical trials see gsk clinical trial register cumulative total patient safety safety efficacy information provided doctors prescribing information year summaries approved regulators addition need use ways communicate results clinical trials healthcare practitioners others use evaluate use medicines gsk corporate responsibility report seirammus fo rebmun approach authorship journal articles concerns ghost writing journal articles doctors put names articles written pharmaceutical companies gsks policy authorship acknowledgements articles must consistent journal guidelines determined level contribution study design data acquisition analysis interpretation writing revising manuscript named senior author paper must actively participate drafting process lead content development retain final approval authority manuscript gsk staff contractors contribute development manuscripts external authors must named article read public policy disclosure clinical trial information authorship journal articles nnuummbbeerr ooff ssuummmmaarriieess ooff ggsskk cclliinniiccaall ttrriiaallss oonn tthhee ggsskk cclliinniiccaall ttrriiaall rreeggiisstteerr ccuummuullaattiivvee ttoottaall corporate responsibility report genetic research patient objective disclose clinical trial monitor safety safety register trial results new products within efficient fully operational worldwide system pharmacogenetic research months product reaching market pharmacovigilance maintained within study genetic variations disclose results trials completed company dedicated teams scientists predispose individuals respond product approved marketing within one year healthcare professionals across world differently medicines research area potential trial completion small number monitor review evaluate communicate safety improve effectiveness postings delayed various reasons including issues medicines medicines patient safety publication scientific journals identifying patients jeopardised safety products assessed clinical likely benefit trials product approved medicine may independent assessment documentation marketing sometimes adverse events occur susceptible sideeffects processes procedures used gsk approval product used large pharmacogenetics relies populating clinical trial register numbers patients policies analysing dna participants conducted external organisation governance framework place help us detect clinical trials results continue engage services organisation act adverse events reasonably treatment collect ensure gsk complies policies associated products see drug safety blood samples potential dna procedures established fulfil governance framework analysis majority phase ii iii drug commitment make information clinical adverse events recorded global safety development trials includes research activities available public database clinical trial database investigated ethics committee reviews clinical pharmacovigilance teams approval informed patient consent helps us monitor balance benefits risks seebenefitrisk management patient safety appropriate respond safety issues ensuring patient safety extremely important changing product labelling communicating take safety medicines vaccines doctors cases actions medical devices seriously sufficient small number cases conduct risk minimisation activities clinical safety medicines trials certain cases may also appropriate medicines part modern life ideal stop clinical trials withdraw medicine world medicine would target disease market see collecting reporting safety disorder meant never anything else data unfortunately despite best efforts scientists medicine yet exist gsk investing number areas emerging science potential improve patient medicines potential risks well benefits safety example pharmacogenetic research see although everyone takes medicine sidebar experience side effects important identify evaluate minimise safety concerns enhancing pharmacovigilance system ensure overall benefits medicine science pharmacogivilance continually outweigh risks known evolving providing new ways enhancing pharmacovigilance pharmacovigilance framework benefit industry regulators healthcare professionals monitoring safety medicines importantly patients enhance pharmaceutical industry two major roles pharmacovigilance gsk recommends managing safety medicines initiatives undertaken increase collect investigate proactively evaluate quantity quality reporting possible information relating side effects medicines side effects medicines healthcare purpose protecting patients professionals patients advising drug safety focus development fulfil legal obligations regulatory electronic patient records would permit authorities reporting individual adverse real time access anonymised data events aes expedited basis andor detection evaluation possible side effects periodically according drug safety regulations country pregnancy registries established health care systems enable rapid collection strive ensure patient interest served evaluation data related possible adverse prompt detection potential safety issue events including birth defects one drugs appropriate communi cation regulators occurs following evaluation research undertaken establish decisions made action taken see effective ways minimise risks medicines collecting reporting safety data including effective ways communicating benefits risks medicines healthcare professionals patients gsk corporate responsibility report corporate responsibility report increased harmonisation pharmacovigilance rules rapid consistent implementation ich guidelines eu us japan eu pharmacovigilance regulation introduced streamline simplify pharmacovigilance reporting requirements europe order achieve necessary industry regulators work together safety monitoring considered competitive area since benefits parties carried highest standards gsk makes new ideas technology available pharmaceutical companies regulators presenting scientific conferences also working third party software suppliers make new advances accessible gsk corporate responsibility report corporate responsibility report ethical conduct gsk committed business practices meet high standards ethical legal compliance ensuring employees behave honesty integrity getting right requires combination effective systems ethical corporate culture understood everyone required conduct business honesty integrity compliance applicable legal requirements find patients consumers doctors governments management certification business ethics report want use medicines companies commitment code conduct reinforced ethical issues rd trust reputation annual management certification programme including policies stakeholders therefore critical business requires managers confirm comply relationships doctors meeting high ethical standards enables us ethics policies programme covers involved clinical trials maintain support retain licence managers worldwide eligible managers disclosure clinical trial operate also helps us attract retain business units completed certification results writing motivate best people articles medical journals unethical conduct could serious legal certification managed electronically non relationships financial consequences company certification tracked followed non governments patient ethics programmes also important element certification typically due extended leave groups risk management good stewardship absence maternity leave longterm sick supply chain standards corporate assets leave access medicines section explains approach business full certification statementis reproduced policies marketing ethics progress embedding background section website website ethical culture gsk covers business ethics suppliers background gsks code conduct management expect suppliers operate high information ethics certification business ethics ethical standards employees see policies supply chainpage code conduct marketing ethics including codes practice policy directtoconsumer european marketing advertising code practice ethical training awareness programmes marketing ethics monitoring compliance systems including gsk markets medicines doctors hospitals channels reporting cases misconduct governments countries us data number employees dismissed also advertise medicines directly consumers disciplined violating company policies specialist sales representatives meet regularly doctors pharmacists inform medicines approved uses code conduct believe sales representatives play important role providing uptodate information employee guide business conduct requires doctors products benefits employees act integrity comply patients however recognise marketing law avoid conflicts interest report pharmaceutical products raises challenging violations law gsks policies issues unethical behaviour provides guidance including particular people concerned specific examples constitutes acceptable marketing pharmaceutical companies exerts unacceptable behaviour undue influence doctors sales employees learn standards representatives always give doctors full induction access guide via company information potential side effects intranet promotion unapproved uses may common despite increased training monitoring read code conductand employee guide oversight business conduct gsk corporate responsibility report corporate responsibility report promotion pharmaceutical products highly us marketing codes regulated several governments extending strengthened policy grants practice summary legislation area instance six us states independent medical education grants full accurate information information require pharmaceutical companies restrict made new center medical education provided approved uses report interactions doctors requirements within corporate ethics compliance medicine must vary prohibiting companies providing department grants medical education based valid scientific meals setting annual spending limits requiring companies mecs hospitals medical associations evidence must transparent reporting similar legislation patient groups must account accurate balanced fair considered many states american percent organisations annual budget objective unambiguous uptodate medical association enables doctors request sales staff permitted deal mecs prescribing activity shared providers independent medical education promotional items pharmaceutical companies recommend speakers education healthcare professionals promotional items must programmes approach addressing issues includes given occasionally following international region must relevant practice medicine revised marketing code gsk employees must comply nominal value must international region ensure meets new ifpma marketing codes practice revised less strengthened policies standards added comprehensive qa help items made employees understand requirements inducement prescribe governing consumer advertising provided guidance employees use medicines medical sales marketing employees receive training healthcare professionals consultants professionals retained consultants gsk ensure good understanding sponsorship healthcare professionals attend marketing policies legal framework conferences appropriate hospitality governing sales activities meetings entertainment europe permitted hospitality programmes monitor compliance updated gsk european promotion travel costs food may including regions feedback medicines code practice march ensure provided meetings doctors sales practices alignment updated efpia code major educational purpose level hospitality must changes include marketing codes practice appropriate pharmaceutical marketing promotional new sections distributing product occasion must provided relevant activity policy applies employees agents information healthcare professionals via healthcare professionals commits us promotional practices email internet spouses children office ethical responsible principled patientcentred prohibiting use competitions prizes personnel prohibits kickbacks bribery inducements guests travel costs promote medicines doctors promotion unapproved uses provided us medicines established new procedure relationships decisions grants patient groups committed publishing medical education policy supported regional marketing gsk funding groups see patient reviewed qualified medical practices codes europe international region advocacyon scientific personnel within japan us codes apply compliance function ethical standards reflect differences market rd structures national healthcare systems strengthened rd policy gifts regulations incorporate principles entertainment policy states primary industry codes practice efpia ifpma purpose meeting must facilitate jpma phrma marketing codes substantial discussion medical scientific topic meals may provided meetings codes available many languages incidental meeting meal must employees access via intranet modest value gsk personnel must copy gsk european promotion present medicines code practiceis available consumer advertising website section explains approach advertising progress prescription medicines us revised procedure making charitable consumer healthcare products markets donations healthrelated organisations directtoconsumer advertising funding external science medical programmes us advertise prescription medicines regions decisions grants must consumers tv print advertisements made relevant medical andor known directtoconsumer dtc compliance personnel sales advertising new zealand bangladesh korea marketing departments also allow limited dtc advertising dtc advertising prescription medicines permitted markets gsk corporate responsibility report corporate responsibility report supporting industry us implemented policy incorporating belong consumer healthcare products codes conduct new phrma guiding principles dtc association us comply code gsk supports efforts advertising prescription medicines states advertising practices nonprescription strengthen marketing standards dtc advertising medicines states advertising across pharmaceutical imply casual attitude towards using medicines industry included begin spent appropriate suggest overthecounter medicine global helped revise amount time educating doctors prevent cure serious disease must international federation healthcare professionals new medicines treated licensed practitioner addition gsk pharmaceutical manufacturers associations ifpma code designed educate consumers policies require claims advertisements pharmaceutical marketing medicine condition consistent product labelling advertising practices gsk member prescribed compares gsk product competitors must newly formed code supported adequate data compliance network accurate supported evidence support implementation gsk consumer healthcare advertising reviewed include information risks benefits ifpma standards copy review committees larger markets training education gsk treatments medical legal personnel smaller helped revise european provide information treatment options markets publication ensure meets federation pharmaceutical industries associations efpia diet lifestyle changes standards code practice promotion referenced prescribing information overthecounter medicines also promoted medicines product pharmacists doctors dentists sales greece gsk greece leading reminder advertisements short advertisements teams prescription weight loss medicine local industry body working mention pharmaceutical brand name promoted preparation approval group set improve medical condition designed treat overthecounter medicine us consumer local code practice permitted healthcare medical sales team completed online korea gsk led efforts training marketing codes practice prior improve korean research dtc television advertisements including audio promoting product based pharmaceutical industry visual components submitted us associations code conduct food drug administration fda review advertising children endorsed least days advance problems gsk guidelines advertising children meet korea fair trade commission dtc advertising identified fda exceed local laws codes practice japan gsk joined executive prohibit advertising designed appeal steering committee fair targeted children legally mandated trade council ethical members public healthcare professionals pharmaceutical drug send comments dtc advertising phrmas minimum age example uk manufacturing industry buy advertising space childrens media office accountability established seeks strengthen compliance supply vending machines primary schools forwarded relevant company office marketing codes accountability reports periodically sports star sponsorship important brands slovakia gsks general comments companies response lucozade sport guidelines state manager slovakia helped fda gsk receive comments people set appropriate example found recently formed local industry association office accountability regarding dtc used sponsorship leads group advertising appeal solely children age sri lanka gsk led efforts employees involved dtc marketing create first marketing code attended training new policy phrma sri lanka chamber principles also developed dtc elearning pharmaceutical industry based ifpma code module future training disease awareness campaigns fund disease awareness campaigns designed increase understanding specific disease linked promotion gsk products revised policies make clear disease awareness campaigns must imply endorsement government agency professional body patient advocacy group without consent campaigns include links third party websites without permission websites contain information uses products outside licence nonprescription products advertise overthecounter medicines oral healthcare nutritional products directly consumers governed national regulations codes practice advertising generally less stringent requirements prescription medicines gsk corporate responsibility report corporate responsibility report training awareness us view directtoconsumer new sales marketing staff us advertising training awareness programmes help completed training existing promoting use prescrip employees understand comply ethics staff received two hours annual refresher training tion medicines directly consumers controversial policies us compliance formal performance critics believe encourages global leadership survey percent objective sales marketing employees people request unnecessary managers said believe people appraised following objective treatment adding burden healthcare systems department show commitment performance integrity consistently follow company policies believe responsible procedures take complete required compliance pharmaceutical advertising specialised training provided employees training timely manner report compliance useful source health working rd manufacturing sales issues manager legal compliance information patients marketing additional regulatory helps increase knowledge requirements addition managers evaluated conditions educates following objective patients treatment monitor success training options regular employee surveys surveyed ensure supervised employees trained countries us us district sales managers dsms play company policies procedures taken dtc advertising important role helping sales representatives required training provide oversight common industry practice resolve compliance questions showed direction supervised employees need ensure products substantial majority dsms good compliance company policies also promoted way understanding compliance issues procedures gsk would disadvantage confident help representatives resolve launch compliance university competitors grey areas survey identified opportunities us sales managers one day programme patients must still consult enhance training resource materials designed improve understanding policies physicians instance provide managers additional ability managers guide staff reduce condition appropriateness training materials increase expertise number breaches policies increase prescription medicine providing effective guidance staff managers expertise detecting compliance issues obtain consent receiving medicines ethics training corrective actions taken early new employees uk us complete international induction training code conduct sales marketing staff continued ensures understand importance receive training pharmaceuticals international ethical conduct day one know deal promotion marketing code involves initial dilemmas seek help awareness sessions induction courses regular ran ethical decision making workshop reminders refreshers facilitated medical staff managers part hot topics training sales conferences programme follow emails sent addition number supplemental policies encourage managers review key points implemented added teams piloted three elearning modules internal intranet community supports ethical leadership within corporate hr visibility international staff training sales corporate ethics compliance teams marketing staff delivered first half rolled managers worldwide regarding updated international code europe training awareness sales pharmaceuticals sales marketing staff marketing europe trained updated promotion employees working sales marketing receive medicines code practice certified extensive training ethics marketing understood revised code policies includes ethics training rd induction training new employees updated performance integrity face marketing codes practice toface induction training rd employees sales employees required pass test completed new existing marketing code starting sales employees worldwide mandatory role course offered languages includes training code conduct conflicts interest detailed training sales representatives acceptance gifts entertainment medicines promote diseases employees external professional activities designed treat regular refresher courses held least year yearly bulletin major types unethical conduct detected actions taken employees us senior managers within european region receive quarterly update number types disciplinary actions policy breaches gsk corporate responsibility report corporate responsibility report launched additional training rd employees monitoring policies governing compliance collection use storage protected recognise strong policies codes practice medical information information held good training guarantee clinical trial participants relating health employees meet standards internal status medical conditions compliance systems designed identify collection use human biological address breaches codes samples data integrity management human section covers safety information role corporate ethics public disclosure clinical trial results compliance department posttrial treatment participants gsk channels employees report concerns sponsored clinical trials suspected cases misconduct ethics training practice address misconduct ethics training designed help employees apply policies real life situations make right number employees dismissed decisions work disciplined misconduct example employees encouraged ask corporate ethics compliance function following questions making corporate ethics compliance department decision promotes effective compliance programmes addresses compliance issues reports problems would embarrassed friends family progress senior management board knew decision made dedicated compliance officer would decision look cynic eight business units rd manufacturing could newspaper headline look like biologicals pharma europe international pharma consumer healthcare japan pharma us still confident right decision pharma addition corporate compliance gsk officer reports directly ceo training employees explore ethical dilemmas compliance officers senior managers direct may face work receive guidance access leadership teams gsk functions help understand appropriate response source expertise anyone one example recent training session question ethics gsk policies european scenarioyou trade conference put international regions supported business card prize draw win network regional country compliance officers grand prize set golf clubs worth local compliance champions enjoy golf would like new set strengthen networks particularly clubs draw sponsored exhibitor eastern europe gsk business keep sales representatives supervised clubs managers regularly monitor educational guidance taking account gsk policy events visits doctors expenses also acceptance entertainment gifts gsk independent monitors review records employees clubs must accepted number key risk areas us internal would better put business card audit department regularly audits sales draw marketing practices globally objectives gsk requires business functional unit translate key policies employee identify significant risks implement effective guide business conduct languages controls manage risks periodically review improve understanding across business risks provide upward communication significant issues arise create company wide compliance training employee guide business conduct us supplement local training reinforce us four sales marketing annual management certification business compliance advisers provide feedback ethics infractions conduct customised training recommend process improvements important link compliance department commercial units compliance data analysis reporting function coordinates monitoring reporting targeting compliance efforts gsk corporate responsibility report corporate responsibility report set strategic tracking analysis addressing misconduct reporting star system gives senior managers corporate ethics compliance department access comprehensive compliance information monitors tracks allegations suspected cases makes easier identify instances non legal ethical policy infractions ensures compliance area take appropriate allegations appropriately investigated action disciplinary action including dismissal taken necessary europe european code marketing practice includes discipline reporting process changed quarterly reporting mechanism markets order provide gsk ability confirm whether breaches code better identify issues resulting formal hr practice occurred severity breaches disciplinary action significant changes include new actions taken prevent category sections precise reporting directions recurrence reports reviewed senior interactive training sessions conducted managers expenses payments doctors appropriate personnel example speaker fees monitored locally improvements information policy summary report market reviewed discipline cases differs information european compliance officer quarter reported previous years overall level dismissals collected similar previous years international directly comparable future reports gsk established monthly review system using hr policy discipline numbers international region senior managers baseline compare policy reviewed resolved number compliance discipline trends issues mechanism many minor issues resolved local level reporting channels employees disciplined policy employees encouraged seek help violations report concerns suspected cases dismissed agreed leave misconduct line company voluntarily known separation management compliance officer confidential integrity helplines offsite post office disciplinary actions included documented box us warnings instances financial penalties reporting channels promoted employees staying company received employee guide business conduct gsk retraining increased monitoring intranet training disciplinary actions included cases employees breaching sales marketing codes cases resulted dismissals contacts compliance functions separations company increase cases resulted documented warnings data analyse compliance trends percent employees regional differences identify appropriate seeking advice information percent corrective actions employees reporting suspected cases misconduct compliance group continues make efforts promote high standards legal compliance ethical behaviour well use integrity helpline compliance resource yearonyear growth percent percent seen contact figures may due greater awareness sensitivity standards doctors raise concerns report unethical conduct gsk sales representatives customer response centres market research via industry associations phrma abpi staff trained deal concerns marketing practices might raised healthcare professionals patients public redirect calls appropriate senior management compliance officer necessary gsk corporate responsibility report corporate responsibility report employment practices goal best place best people best work central business strategy underpins success people greatest source competitive advantage skills intellect essential gsk discovering delivering best new medicines vaccines successfully marketing selling prescription consumer healthcare products employment gsk employs people gsk spirit awards gsk countries goal company working mothers top expect employees meet high standards talented people apply energy best places work us way carry work gsk gsk passion make difference world britains top employers spirit defines culture principles competitive reward important independent survey run expect employees work include factor influences ability recruit retain corporate research foundation guardian talented employees performance integrity newspaper ranked th section explains approach employment innovation entrepreneurial spirit britains admired performance including companies accountability achievement management today ranked initiatives increase diversity inclusion passion sense urgency th training development talent management best companies work continuous learning development awards germany internal communication communi regular performance appraisals assess whether hungary ireland mexico cate employees get feedback russia employees upheld principles flexible working arrangements wellbeing requirements code conduct work human rights campaigns resilience programmes support healthy see ethical conduct code best places work gay lesbian bisexual workforce results affect bonuses career progression transgender employees gsk breakdown global employment business end received perfect score december employee surveys business number function employees regular employee surveys help us monitor gsks maufacturing culture gauge employee satisfaction assess effectiveness employment policies selling global leadership survey gls sent gsk rd managers every two years available nine adminisration languages managers took part percent response rate survey tracked total views previous two surveys findings global companies crosscompany database database includes topranked companies several industries including pharmaceuticals automotive banking energy normative database responses around three million employees countries gsk corporate responsibility report corporate responsibility report key survey findings survey showed managers gsk satisfied company managers companies took part gsk participants also satisfied overall responses average percent higher industry gsk gsk gsk benchmark favourable favourable favourable overall satisfaction gsk people department show commitment performance integrity na proud part gsk people department committed enabled make meaningful contributions na report unethical practices without fear reprisal amount work expected right gsk company great people best work na satisfied recognition receive good job sufficient effort made get opinions thinking people work leaders department act teacherscoaches champions development na receive ongoing feedback helps improve performance diversity inclusion improvement plans survey results reviewed corporate aim create inclusive working environment executive team identified two key areas gsk employees diverse backgrounds focus flourish reducing unnecessary bureaucracy within diversity benefits business workforce across businesses diverse backgrounds cultures outlooks helps us better understand needs different leadership visibility defined drive patients customers delivering genuine managers spend time teams equality opportunity sure visible respective best people right jobs businesses reinforce commitment diversity business unit function developed inclusion di action plan address areas improvement corporate executive team endorses global policy di support activities initiatives annual multicultural marketing diversity awards companywide di policy practices available view employees intranet monitoring reporting data gender diversity management grade worldwide ethnicity us uk gsk corporate responsibility report corporate responsibility report reinforcing gsk spirit states ethnic diversity value draw differing knowledge us minorities defined blacks hispanics perspectives experiences styles resident asians pacific islanders american indians global community alaskan natives made percent workforce compared percent di steering teams uk us run percent average awareness campaigns training closest comparator us chemical industry employees diversity champions business unit among field staff employee networks provide insight support diversity objectives background information approach di available website us conduct annual survey employees selected random gauge progress inclusion resilience survey achieved percent response rate percent agreed workgroup climate diverse perspectives valued percent agreed manager demonstrates ability manage diverse workforce uuss mmiinnoorriittyy gender diversity uk ethnic minorities defined uk gender diversity management commission racial equality cre accounted worldwide percent employees compared women positions percent percent cre management grades held women defines ethnic minorities anyone identifying white british figures census show percent population ab bands england wales ethnic minority c c c c total management grades corporate executive teamsenior vice presidents vice presidents director grade manager grade positive trend increased female representation management positions reflects impact gsks di strategy across businesses effect flexible working policies uk ethnic minorities attracting retaining women supported us di survey percent employees agreed manager alternative measure diversity number enables flexible innovative solutions employees define non managing work personal life white percent gsk uk employees defined nonwhite compared years annual women percent percent science event us fostered positive mentoring relationships gsk female age scientists female students aspiring enter advance new age discrimination regulations science fields also exposes students handson uk carried comprehensive review reallife laboratory research environments policies practices consulted uk enhances gsks ability attract retain information consultation forum result women fields science number policies amended updated extensive training provided hr professionals changes communicated managers employees ensure understand implications new law gsk corporate responsibility report corporate responsibility report disability committed offering people leadership training included disabilities access full range recruitment managers attended four leadership edge career opportunities gsk uk programmes awarded two ticks symbolfrom jobcentre plus partner employers forum managers attended six inspirational disability interest groups ensure leadership workshops focused inspiring disability confidentorganisation motivating people high performance multicultural marketing diversity managers attended new manager awards experienced manager training annual multicultural marketing diversity managers attended hot topics awards fifth year inspire staff find harnessing power real conversations creative ways reach wider audience employees customers communities managers attended hot topics art self leadership awards given several categories including employee attraction development retention development multicultural marketing sales community regular performance appraisals reward strong outreach diversity ambassador performance identify training needs help entries awards since employees set objectives aligned employees received gsk diversity business priorities twothirds gsk ambassador award leading diversity efforts employees receive annual performance appraisal passion innovation impact performance development planning pdp programmes employee networks employee networks integral part di pdp includes assessment well employees programme networks support professional growth implemented gsk spirit principles participating employees provide forum use define culture impact employees similar backgrounds meet bonus payments affect future career discuss issues shared concern development several networks particular diversity focus employee turnover including networks asian african american number teams focus issues hispanic gay lesbian bisexual transgender affecting employee retention example employees well benefiting participants management people different age groups networks act source expertise diversity development promotion female issues people gsk minority employees employee network executive sponsor rewarding strong performance helps setting achieving goals obtaining performance related pay share ownership resources promoting network objectives schemes help us attract retain best people among senior management gsksponsored generate culture ownership among networks regardless affiliation open employees countries employee share gsk employees ownership schemes exist level participation high talent management talent management processes help us identify employee development develop leadership candidates identify talent management highest performing employees business function annual talent management gsk invests training development enable cycle talented individuals take part leadership employees perform best ability programmes exposed top management support career progression work programmes chief executive hard attract retain best brightest forum people gsk help develop potential training provide jobrelated training courses employees leadership training managers employees enrol training programmes mylearning intranet site available uk us countries registered system course completions gsk corporate responsibility report corporate responsibility report internal communications good internal communication important similar forums countries achieving business objectives well creating national practice open inclusive work environment communicating corporate responsibility range communications channels keep employees put employees date company news responsible business policies practice enable give feedback communicate outside world employees include also important stakeholders right want know progress mygsk global intranet site provides news responsibility issues updates qa section employees put questions directly keep employees informed corporate ceo senior executives jp garnier responsibility regular news articles gsks chief executive answered questions gsk intranet articles spirit magazine employees behind news section presentations departmental groups gsk intranet gives companys position summary cr report distributed important issues linked press stories employees gsk webbroadcasts gsk senior manage ment including executive team members employees major employee health sites protection promotion wellbeing spirit internal magazine reaches around employees ethical obligation important employees throughout company contributor goal employer choice four times year many sites also produce local philosophy also supports business strategy newsletters healthy resilient workforce drives confidential feedback mechanisms enable positive business performance increasing employees raise concerns include employee productivity attendance healthy integrity helpline see ethical conduct workers also reduce health care insurance costs regular employee surveys see healthy high performance healthy culture townhall sessions consider four dimensions health vitally employees levels company important high performance physical emotional hosted senior management employees mental spiritual people need physically opportunity discuss progress energised emotionally connected mentally focused business raise questions give feedback spiritually alignedmeaning sense track effectiveness communications purpose linked four dimensions employee surveys monitor factors enable high performance questions employees put senior managers factors range fitness nutrition self qa pages mygsk ensure awareness time management deliver pick potential areas concern also track programmes corporate athlete readership news stories mygsk help health risk assessment hra directed improve relevance interest content improving factors measuring risk reduction health impacts employee consultation consult employees changes affect driving healthy culture gsk starts europe discuss business developments leadership want companys leaders european employee consultation committed continuous development forum eecf eecf received updates physical psychological well gsks global business leaders reviewed effective leaders role models proposals progress reports number employees european initiatives distribution medical resilience also national consultation forums use term resilience describe skills established uk information behaviours needed successful highly consultation forum provide information pressured environment set skills companys progress plans help helps prevent workrelated mental illness stimulate constructive dialogue employee leading cause illhealth leading time representatives within uk forum made away work resilient employees manage elected employee representatives work home demands effectively minimise seven managers meets three times year adverse health affects stress date reviewed areas employment policy changes uk pension arrangements preparations supporting employees event flu pandemic gsk corporate responsibility report corporate responsibility report identify manage challenges developed new global management role employee resilience mental well focused improving health employees accordance gsks global resilience mental around world developing health well well standard majority gsk sites resources sharing best practice programmes reduce workplace pressures help employees achieve good worklife balance developed health risk appraisal tool time management training flexible working used sites options health awareness since work related mental illhealth percent worked world heart federation joint project two sites india team resilience programme available ground breaking threeyear study look languages helps gsk teams take control two different interventions aimed reducing work avoid excessive pressure effects chronic disease identifying lead stress first step assess seven sources effective interventions sustainable pressure impact performance transferable companies health identify extent pressure team community programmes facing team members consider issues creating excessive pressures began global health education webinars web managed effectively objective based seminars avoid pressure help ergonomics achieve high performance avoid becoming reduction musculoskeletal illness injury strained overwhelmed due excessive work continues key area focus demands one leading causes time away work end people set target reduce number teams gone prog illnesses injuries percent year ramme results show significant improvements better workplace job design science first two years programme called ergonomics prevent musculoskeletal injuries illnesses well increase efficiency reported pressure due worklife conflicts fell productivity percent ergonomics improvement teams include cross participating staff satisfaction increased functional team members impact work percent work environment designed percent increase willingness among staff implemented established experiment new work practices ergonomics improvement teams manufacturing sites around world ergonomics teams taken profile second workshops provided regions us uk time showing improvement seven france india malaysia increase inhouse sources pressure percent ergonomics knowledge expertise percent sites share good practices work ranging also provide training programme support commercial operations laboratory research personal development help individuals become manufacturing via intranet site called global resilient pre postassessments pilot ergonomics community intranet site provides employees found improvement access latest information ergonomics elements measured greatest good practices validated tools practitioners improvement employees sense relaxed including online computer ergonomics risk engaged two months number assessment tool online assessment used people felt less pressured rose almost fifth gsk sites globally employees personal health worldwide used tool past two programmes aim improve health years assess computer work take employees families benefits steps needed improve workstations business increased employee commitment ergonomic principles integrated designs productivity reduced costs illhealth including major engineering projects furniture support includes onsite health fitness centres procurement takes ergonomics consideration flexible working arrangements family support ensure appropriate furniture equipment services healthcare benefits focus prevention selected access innovative proven treatments hiv example us employees receive free provide antiretroviral treatment hiv immunisations cancer screening help smoking positive gsk employees full parttime cessation regular check ups assist families countries treatment employees suffering chronic diseases available adequately consistently medical plans continue treatments local healthcare system background information see employee access antiretroviral drugs gsk corporate responsibility report corporate responsibility report developed awarenessraising material programmes cover wide range health use peer educators project funded safety hs aspects providing safety training positive action delivered national aids sales employees working employees trust gsk employers use materials improve general health section reports deliver training ways address problems specific health safety issues see hiv aidsrelated stigma environment section information manage environmental materials based experience gsk broader ehs issues kenya adapted versions used india central america french version promoted gsk foundation across francophone africa health safety flu pandemic preparedness management gsk committed supporting governments health authorities around world well manage health safety employees minimising impact integrated environment health safety ehs global influenza pandemic management system system incorporates ehs employee health policies ehs vision gsk play vital role providing potentially life global ehs standards ehs plan saving medicines vaccines flu well excellence sets strategy improving ehs continuing produce critical medicines performance renewed plan invested billion expanding extended see ehs seasonal flu vaccine capacity developing avian management systemin background pages flu vaccine increasing production capacity antiviral flu treatment relenza see ohsas certification contribution society one additional site achieved certification international health safety standard also developing plans ensure ohsas brings total number continuity critical business operations manufacturing sites certified processes safeguard health gsk pharmaceutical consumer manufacturing employees dependents key contractors sites certified sites argentina china sites every gsk market developing egypt france germany india japan kenya comprehensive country plan covers local mexico poland saudi arabia turkey usa business units plans include annual seasonal uk voluntary certification process flu vaccine travel health programmes measures replaced plan require manufacturing reduce infection risk work management sites certified sickness absence provision treatment course antivirals possibly vaccine training awareness employees immediate family members training targeted match employee worldwide markets expected responsibilities employees responsibility completed plans third quarter hs issues receive regular training initiatives areas ergonomics chemical exposures driver safety handled regional meetings hs staff turn train employees manufacturing research sales health safety divisions corporate ehs employee health staff work arrange annual meetings determine training issues provide training materials health safety employees contractors absolute priority gsk also want employees aware health programmes systematically assess risks safety personal lives employee bulletins associated operations monitor announcements myehs website ceos performance aiming learn causes ehs excellence awards programme health incidents take action protect employees safety week activities aim raise employee others workplace awareness issues wearing seat belts careful electricity using ladders ultimate aim eliminate workrelated appropriately injuries illnesses ii focusing reportable incidents serious conduct health safety week every first aid necessarily result time work october coincide european health lost time main measure safety week fire safety awareness month performance used past believe united states information kits sent addressing causes minor events help sites help develop ideas plan activities eliminate risks hazards lead employees sites fewer reportable cases well losttime ii cases countries took part health safety new target reduce reportable week activities included safe driving education ii percent year still monitor training fire evacuation ergonomics first aid report lost time incidents longer awarenessraising noise healthy eating target measure lifestyles gsk corporate responsibility report corporate responsibility report excellence awards risk assessment guideline revised employee health management chief executive officers environment health aligned risk assessment requirement uk resilience policy safety ehs excellence awards recognise quality group employee health management developed wideranging reward innovation gsk sites winning entry self audit training workshop self resilience policy successfully ehs initiative health safety category auditing conducted ehs network meetings addresses worklife balance featured pressure issues benefit management system elements agreement gsk employees see ceos ehs excellence award global manufacturing supply target define resilience ability awards programme winners previous ohsas certification along iso successful personally years see employee health professionally high certification pharmaceutical resilience pressured fastpaced consumer manufacturing sites continuously changing environ ment policy encompasses team resilience process personal resilience workshops ehs audits focus work home injury illness rates balance fulfillment aim conduct ehs audits operational causes project global site least every four years carry application although focus frequent visits selected sites depending main measure injury illness number first year uk assessment risk issues raised previous reportable cases require sites report us second third year audits express rate per hours worked programme project offered globally auditors signal critical findings conclude target reduce reportable injury currently active india japan high probability incidents illness rate percent year end china brazil argentina finland potentially serious consequences made five czech republic nigeria findings involved serious israel reached deficiencies also measure number days lost employees injuries illnesses provides indication project first place controlling exposures high hazard chemical severity incidents although ehs initiative health agents rough guide example illness could lead safety category ceos ehs managing dust explosion risks related dust permanent hearing loss disability without excellence awards collector resulting significant lost time managing fire explosion risks main data cover gsk employees contract flammable liquids workers directly supervise separately report data contractors work gsk preventing falls elevated locations sites supervise staff contractors data site actions monitored ensure covered sgs verification data appropriate actions taken mitigate collected pharmaceutical risks ensure ongoing compliance none consumer manufacturing sites critical findings become delinquent greater biologicals manufacturing sites pharma days overdue ceutical consumer research development sites major office locations smaller actively track audit findings identify offices improvements followup audits sites scoring less percent also provide causes injuries illnesses increased support audit team including injuries without lost time arise mainly followup visits ensure progress discussions slips trips falls overexertions strains senior business management increased motor vehicle accidents site resources many sites require several years losttime illness stems mainly mental illhealth put adequate systems programmes place musculoskeletal problems primarily repetitive areas strain injury musculoskeletal illness main introduced continued specific work cause reportable illness lead following areas achieve improvements days work accounting third total chemical agents monitoring determine exposure ensure adequacy respiratory highlights protective equipment may required sites countries losttime unit operations engineering injuries illnesses year addition controls implemented one site india achieved million hours resilience rollout tool assessing worked without losttime injury illness team resilience training ehs network one site india achieved million hours meetings worked without losttime injury illness ergonomics training ergonomic risk one site us achieved million hours assessment network meetings well worked without losttime injury illness regional training gsk corporate responsibility report corporate responsibility report performance fifteen sites argentina canada india five year trend employee fatalities recorded injuries philippines singapore spain sri lanka uk illnesses total us achieved million hours worked without fatalities incidents compared losttime injury illness respectively employees lost working days reportable injury illness rate percent incidents gsks injury illness target performance placed us third quartile benchmark industry group means need improve baseline working time lost investigate circumstances fatalities injuries illnesses rate lost time injuries serious incidents assess illnesses per hours learned reduce risks also issue global worked alerts posted intranet site communicate injuries baseline information could help prevent similar incidents illnesses without lost time sites rate injuries illnesses without lost time per hours worked injuries illnesses per hours worked target lost calendar safety programmes days injuries calendar days lost illnesses systematically assess risks anticipate potential rate calendar days lost per hours worked reportable injury illness rate accidents put programmes place minimise year ii per hours learn investigating causes see data table details accidents make improvements accordingly section cover four key areas driver safety process safety material hazard information chemical exposure driver safety sales representatives drive long distances every year therefore particularly risk serious incidents involved workrelated road traffic incidents fatalities driving accidents resulting fatality resulting lost time fatalities accounted percent losttime injuries november two employees contractors died result injuries suffered explosion compliance tool drivers called ehs fire caused ruptured butane cylinder used essentials includes instructions guidelines cooking canteen agbara nigeria driver training vehicle selection risk assessment consumer healthcare factory thorough accident reporting well information investigation conducted global audit continue use implement driver safety team improvements identified progress programme around world implementing improvements monitored around two thirds gsks commercial businesses audit team learnings incident extensive driver safety programmes place shared across gsk include driving licence checks guidance april one sales employee india died result use mobile phones vehicles driver safety head injuries suffered motorbike training tracking reporting incidents collided another motorbike working ensure sites high standards place irvine explosion concentrating improving areas accident serious explosion occurred irvine uk site injury reporting driver training february involving placebo batch used test plant conditions controls two operators countries provide motorbikes injured event thoroughly scooters employees produced gsk investigated learnings shared improvements motorbike rider safety manual made uk regulator hse considering translated distributed employees countries course action prosecution possibility bangladesh india indonesia pakistan vietnam countries also fully amputations implemented gsk requirement every driver three incidents involving gsk motorbike wear helmet continue employees resulted partial finger follow monitor implementation amputations caused work equipment motorbike safety programme gsk corporate responsibility report corporate responsibility report process safety source percent unit operations process safety programme ensures safety handling high hazard compounds built manufacturing research employees need wear protective development processes programme based equipment hazard identification control risk substantial progress assessment recruited number regional launched major review process safety hygienists deliver improved occupational strategy following explosion hygiene service businesses around world irvine factory encompassed establishing baseline performance consistency design standards developed deployed across evidence basis safety including business tracking tool monitor progress gaps documentation installation checks towards respirator free completion chemical risk assessments skills competencies process safety enhanced collaboration control change nonroutine operations engineers occupational hygienists culture issues awareness attitudes levels ensure control solutions behaviour implemented material hazard information revised updated guidelines focused preparation new business control measures legislation significant impact begun build occupational assess communicate material hazard hygiene network bringing specialists information continue publish ehs together held first network meeting information key products safety data occupational hygienists ensure common sheets pharmaceutical approach understanding across consumer healthcare products sold businesses us europe available website see safety data sheetsfor information engaged new product introduction teams ensure new using alternatives animal testing installations meet respirator free standards occupational toxicology programme example assessed chemicals see approach occupational potential cause skin andor eye irritation hygiene control chemical exposures workforce assessments conducted background pages without use laboratory animals using information chemical structures novel human tissue tests occupational toxicologists used information establish workplace exposure limits unique gsk materials support commitment ensure products adversely affect environment see pharmaceuticals environment enhanced environmental hazard testing programme include number new studies aimed assessing long term effects aquatic organisms addition due new eu technical guidelines conducting extensive environmental testing new drug substances occupational hygiene control chemical exposure exposure chemicals resulted respiratory skinrelated losttime incidents cases result lost time together accounted percent workrelated illnesses developed strategy control chemical exposure sets plan achieve respirator free status validated control gsk corporate responsibility report corporate responsibility report supply chain supply chain complex suppliers worldwide ranges major strategic relationships suppliers manufacture active pharmaceutical ingredients intermediates raw materials packaging gsk medicines local contracts goods services office equipment cleaning security gsks supply chain endeavour ensure supplier selection gsk manufactures sells suppliers follow high standards critical suppliers must pass detailed assessments diverse range products gsk regards environment selected well looking means source wide health safety ehs loss prevention human quality assess policies procedures range suppliers example rights given size global scope supply health safety human rights environmental products agricultural chain challenge recognise issues includes use questionnaires sourced materials suppliers meet standards see supplier site reviews quality audits ehs audits facilities blackcurrants milk performance directly supply gsk petrochemicals complex chemical compounds work suppliers issues contract manufacturers must also approved active ingredients approach includes applicable regulatory authority pharmaceuticals start manufacturing gsk medicines volumes high volume preassessments start working tailormade packaging new supplier plastics lower volume inclusion human rights ehs requirements raw materials flavours supplier contracts services suppliers supplier contracts temporary workers cleaners review ehs human rights routine research companies supplier engagements ehs professional advisors supplier contracts contain requirements based buying service ehs supplier audits global ehs standards providers start outsource services previously supply base large complex human rights managed inhouse possible engage directly suppliers supplier contracts contain human rights clauses issues focus critical suppliers based international workplace norms critical suppliers contract manufacturers international labour organisation conventions suppliers present greatest risk gsk uns universal declaration human rights one following issues read human rights clauses background section website threats continuity supply new local central supplier contracts hazards associated manufacturing worldwide include human rights clauses processes materials added contracts existing suppliers environmental impacts renewed contracts renewed threeyear cycle vast majority contracts regulatory requirements include clauses relevance supply essential medicines engagement auditing suppliers based primarily europe north provide contract manufacturers america asia account approximately information ehs risks associated percent total supplier spend gsk materials producing handling expect critical suppliers work high inform suppliers ethical requirements standards produce uninterrupted supply policies supplier booklet working materials services gsk gsk includes ethics policies explains safety effectiveness availability medicines gsk employees prohibited accepting gifts could affected reasons important entertainment suppliers asked respect forge longterm relationships position apply standards undertake regular monitoring assess progress business interactions gsk allow intervention necessary countries send letters suppliers local festival season making aware policies asking refrain sending gifts providing entertainment gsk corporate responsibility report corporate responsibility report consider ehs human rights issues ehs acceptability criterion key suppliers routine interactions critical suppliers contract manufacturers scoring least percent interactions include ongoing supplier reviews well ehs quantitative audit scheme ehs followup visits procurement quality ehs performance identified unacceptable less staff also hold global regional supplier percent progress required ehs risks review meetings senior gsk managers impacts considered managed robustly address interact suppliers key issues sites considered acceptable suppliers contract manufacturers started pilot project assess risk human rights issues occurring among wide range performance noted suppliers services decided focus sites audited range audit scores following two areas suppliers percent percent eleven suppliers failed meet percent ehs suppliers outsourced business processes acceptability criterion companies starting work suppliers india either progressed supply work includes providers outsourced services underway ensure improvements made example accounts payable department managed indian supplier well providers ehs audits human rights issues technology professional services since significant concern noted growing important area focusing training gsk procurement teams ensuring select right suppliers important employees understand strong reputations employee satisfaction standards provide training procurement research shows suppliers work staff part sourcing group management typically lead way surveys best indian programme explains develop sourcing business process outsourcing employers strategies criteria supplier selection suppliers promotional gift items including human rights ehs training many gift items sourced indian compulsory new procurement staff business sourced within india launched new training effective industry higher risk use child labour contracting explains requirement implemented process unannounced human rights clauses included supplier spot checks suppliers often contracts compulsory procurement night result spot checks staff expect everyone completed agreed corrective actions suppliers training end improve standards area reporting suppliers ehs performance ehs audits tried collect ehs data key suppliers conduct regular environment health safety past five years limited audits critical suppliers contract manufact success suppliers either collect data urers pharmaceutical consumer healthcare use manage ehs programmes products priority undertaking audits based identify impacts specific manufacture business ehs risks including factors related gsk products data received continuity supply hazards presented processes suppliers often reliable materials regulatory regimes essential conduct survey suppliers medicines focus higher risk request corporate responsibility suppliers committee audit committee board quantitative evaluation made sites determine suppliers provided ehs standards protocols acceptance criteria us information want understand place sites used supply suppliers impacts well measure total ehs unless minimum performance levels met footprint processes generate recommendations made following audits products ie gsk supplier facilities progress monitored particular focus working ribenasuppliers poorly performing suppliers performance reviews wildlife trust improve biodiversity blackcurrant undertaken check progress help drive farms understand overall environmental continuing improvements sites impacts operations see case study means least annual visit section website details supplier performance assessments conducted suppliers active pharmaceutical ingredients intermediate materials global pharmaceutical supply chain ten uk europe asia region six sites supplying products materials audited uk eu us one asia one south africa gsk corporate responsibility report corporate responsibility report environmental management vision achieve sustainable competitive business advantage environmental sustainability leadership excellence aim reduce environmental impacts address broader sustainability issues climate change product stewardship material energy efficiency qa discover develop manufacture sell plan excellence pharmaceutical consumer products launched ehs plan excellencein requires significant resources james hagan set strategy improve ehs need understand address report vice president corporate performance tenyear period environmental impacts include issues environment health safety reviewed first five years performance renewed common manufacturers use plan second stage extended energy water waste handling also need consider potential impacts certain chemicals release volatile organic began review plan excellence compounds vocs chemicals extensive consultation key internal inhalers damage ozone layer external stakeholders encouraged us adopt contribute climate change industry higher aspirations align ehs objectives specific impacts release closely business strategy pharmaceuticals environment use first five years plan established patients fundamental programmes protect employees top environmental systematic approach management communities environment priority gsk issues crucial control needs renewed plan includes commitment priority manage consistent long term important stakeholder engagement strengthens focus issues properly looking people move away controlling emissions sustainable environmental practices plant processes context longterm strategic plan processes developing implementing new operational efficiency requires new approach processes efficient therefore use manufacturing processes means working less raw material produce less waste one move incorporating environmental performance since gsk formed asked operations first steps toward environmental sustainability process design moving compliance risk worldwide contribute long term goal management adding value creating new creation selfregulating opportunities example want move overall responsibility environmental issues framework programmes treat hazardous waste stream ie policies standards guidance rests corporate executive team choosing processes produce hazardous audits etc defines board board champion environment waste believe operate health safety ehs jp garnier chief legal compliance basic executive officer rupert bondy general counsel renewed plan designed complement foundation identified operational champion ehs corporate business strategies contains three ehs key risks gsk employee chemical exposure process safety executive team corporate responsibility aspirations gsk ergonomics driver safety committee corporate ehs department ehs fundamentals embedded continue work environmental issues managed together business believe produce years come health safety integrated ehs sustain high ehs performance need discussions system aims ensure issues risks combine structured ehs systems external stakeholders identified standards established adhered attitudes values create positive ehs ehs issues said climate change energy conservation training provided targets set audits culture achieve need embed ehs pharmaceuticals conducted awareness systems gsk activities environment use hazardoustoxic chemicals ehs policy vision global ehs environmental sustainability believe key external challenges standardsset overall framework provide need embrace environmental sustainability worked complete core sites ehs management toolkit driver competitive advantage programmes ehs contains instructions descriptions appropriate define principles management systems achieve procedures help comply standards environmental sustainability progressively improvement targets integrate business translating time move next stage background information approach practical action line advancing qa continues next managing environmental issues available knowledge environment health safetysection website gsk corporate responsibility report corporate responsibility report open transparent ehs external business sector develop objectives next step expand relations believe external support corporate targets develop focus improving use stakeholders legitimate interest specific short mediumterm plans achieve natural resources step towards sustainability thats companys ehs affairs ready individual sites may also set local targets complex access relevant information contribute business target opportunity dialogue issues working material use annual action plans focus efforts efficiency production concern also believe building selected priority issues theme see energy also open relationships partnerships lead embedding ehs business following initial critical component business opportunities failure engage gsk adopted life cycle focus fundamentals first years may damage reputation approach investing energy plan efficiency renewable energy aspirations supported strategic theme ehs stewardship see fact ceo objectives performance targets areas requested review means caring present thinking energy saving measures progress targets future make decisions building excellence use renewable energy ehs plan excellence initially set targets time maintaining highest possible product stewardship another areas interim targets standards everything business sector aspect sustainability encourage culture accepts need focus issue see report progress responsibility incorporating ehs pharmaceuticals targets environment see planning business processes plan next years aligned highlight gsk business drivers desire move corporate ehs work businesses approval second stage plan excellence towards environmental sustainability determine elements environmental see first introduced new targets sustainability need focus begin stage plan since promote environmental sustainability principles focused fundamentals material efficiency targeting efficiency throughout business improved performance simultaneously target resource consumption air many areas need emissions water pollution waste disposal continue pilot programme developing second stage safety concerns distributing product stewardship guides plan keep keen marketed products focus maintaining ehs audit scores measure improvements based success management systems approach expand programme discussions ehs foundation new annual external stakeholders beyond uk rest improvement targets improvement targets across europe us established improvement company new targets manufacturing new baseline see product stewardshipsection medicines move us background web pages toward goal sustainability tangible standpoint annual reductions per sales manufacturing function gms accepted challenge energy board directors iso stakeholder engagement ohsas certified solid waste embed management water stakeholder engagement plays important role systems business manage ehs section reports also created new ehs air emissions volatile engagement specifically ehs issues see director positions gms organic emissions engagement stakeholders managing biologicals sit executive teams help cr section details engagement wastewater chemical ehs integral business corporate responsibility issues oxygen demand decisions addition inclusion dow jones qa continues next material efficiency sustainability index uk ftsegood achieve average material efficiency glaxosmithkline rated business manufacturing processes new products introduced environment bie premier league field participating companies rating indicates extent interpret environmental cumulative targets responsibility way manage business ozone depletion elimination environmental performance ehs audit scores frequently engaged ad hoc meetings range external stakeholders average help us understand views identify minimum emerging issues stepped internal external engagement ehs issues longer targets areas created formal stakeholder panel uk provide perspective ehs performance global warming potential replaced panel facilitated environment council target energy efficiency independent charity members represent hazardous waste addressing customers suppliers regulators public interest hazardous waste new material groups investors plus four senior ehs efficiency target representatives gsk gsk corporate responsibility report corporate responsibility report plans systems arent provides opportunity ehs experts engagement ehs professionals helps us enough across gsks businesses meet stakeholders work details programmes energy theyre first need discuss emerging ehs issues feedback initiatives great people used developing ehs plan excellence right qualifications training surveyed staff involved ehs working issues also panel meets every six months assess success communications right culture discussions covered identify areas improvement also senior management completed internal review corporate support promote right engagement strategy behaviour investment environment health safety cehs taking position need public position papers climate communications wont compromise changeenergy management management ehs framework documents received high environmental protection hazardous chemicals pharmaceuticals employee safetywe seeing marks usefulness source information environment final versions approved consciousness environ ehs communitywebpage web gsk management published ment health safety really needs userfriendly becoming embedded gskcom relaunch site business theme serious process safety incident irvine seen found high awareness ehs site see health safetysection reflected enhanced attitudes plan excellence ehs programmes chemical business ehs strategic plan ehs agents process safety ehs reward moving bolting controls recognition programmes theme existing processes building ehs performance central sustainability people said needed operation culture ehs aligns gsks business direction clearer messages especially priorities change central second relationships overall mission stakeholders repeatedly highlighted view stage year plan corporate ehs department gsk means need important gsk address broader issues address addressed issues people climate change sustainable qualified trained aligned development beginning address broader also took feedback company wide plantsour infrastructure aspects sustainability example work gsk employees develop ehs properly designed installed material efficiency strategic plan maintained processes systems management plan extend stakeholder engagement engagement regulators approach identifies risks activities us europe beyond gsk keen see proper measures place develops programmes next years beginning us see protect environment safeguard manage risks stakeholder engagementbackground pages development launch new medicines priority time regulations need workable theme ehs local engagement industry avoid unnecessary cost bureaucracy stewardship means many sites also engage stakeholders want embed locally activities open days collaborate regulators help new culture business develop effective controls newsletters community projects example people really understand dresden site conducted intensive engaged regulators uk shortterm exercise need communications local community ahead governments work improve regulation vision understanding doubling manufacturing capacity flu business submitted comments ehs longterm impact vaccines construction activity particularly regulations consider reviewed everything sensitive site residential area practicability hosted visit better need think work third place ceos ehs excellence regulation commission one pilot plants environmental impacts awards community projects demonstrate issues also climate change embed inherent safety whole participated house commons select conducted survey ehs stakeholder life cycle products committee inquiry work engagement gsk sites around world raw material waste environment agency change reflect found sites engage frequently gsk manages ehs ehs local government emergency services worked trade associations including benefits gsk example neighboursresident associations local environ british european us pharmaceutical industry addressing climate change mental advocacy groups local business ehs groups improved energy partners sites reported open dialogue efficiency benefits engaged consultation process communities helps build strong relationships environment also european unions regulation registration financial benefit gsk dispel preconceptions particular reported evaluation authorisation chemicals reach beneficial involve local communities qa continues next globally harmonised system ghs environmental risk assessments develop classification labelling chemicals gsk ment emergency response plans site waste supports aims initiatives protect management plans human health environment pleased internal engagement outcomes efforts made engage gsk staff throughout parties achieve workable regulation continue business several ways includes discussions play part development supporting business leaders debate agree way guidance reach forward ehs gsk especially agree annual action plan position papers specific issues energy gsk corporate responsibility report corporate responsibility report welcome introduction formal guidelines awareness gsk planning move conduct environmental risk assessment raise profile environmental issues beyond basic environmental established eus new medicines variety means including ehs framework protection address sustainability broadly legislation gsk lobbied environmental plan excellence chief executive mentioned impacts pharmaceuticals regulated solely officers ehs excellence awardsscheme see side first step toward sustainability european agency evaluation bars next two pages first place concerns efficiency medical products also winners use materials proposed reach framework would lead energy manufacturing duplication effort place unnecessary also run earthweek every june coincide processes new world environment day send target double efficiency burden pharmaceutical industry information kits sites help develop manufacturing new details public policy see managing ideas plan activities sites products introduced date hope cr section see countries celebrated earthweek activities starting use raw involving employees materials renewable examples activities resources rather petrochemicals gsk site mississauga canada celebrated distant future training awareness earthweek planting seedlings small want using biological transformations rather raising employees awareness environment trees indigenous local area chemical synthesis health safety issues improving skills involving employees needs happen inherent training key parts ehs gsk employees civac consumer safety built programme critical embedding healthcare site mexico raised framework building ehs culture throughout environmental awareness group local business employees levels need school children showing understand ehs issues working separate household waste recycling environment example employees need understand properties hazards necessary cover ehs issues regularly ehs bulletins precautions associated chemicals articles gsks internal magazines gsk spirit handle handle waste need know espirit encourage employees consider properties regulations govern disposal environmental issues outside workplace materials recycled minimising household waste saving energy water help employees deal issues meetings bulletins information intranet information see ehs communicationon site well specific training events background pages ehs standard training intranet site myehs community contains links range programmes including ehs managerinformation system contains policies standards guidelines tools training materials examples best practice news also provides customised management reports ehs performance site training training takes place site level programmes routinely included induction training new employees ehs training also accessible mylearning gsks online training service carried additional ehs manage ment training consumer healthcare regional pharma supply organisations made site visits oneonone training use ehs managersoftware system ehs managers encouraged attend conferences training programmes sponsored local environmental organisations academic institutions gsk corporate responsibility report corporate responsibility report barnard castle uk ehs excellence awards site made huge progress reducing environmental ceos ehs excellence awards recognise weaknesses identified audit auditors impacts several years reward gsk sites show leadership ehs monitor sites progress implementing plans cutting electricity use programme expanded include internal auditors certified lead auditors percent gas percent aspects sustainability awards recognise international environment health water consumption percent people done exceptional work safety management standards iso promoting implementing ehs projects ohsas sites also expected conduct site used energy audits highlight innovation examples good practice routine self audits ehs programmes identify potential savings improvements heating ehs management share sites majority audits conducted using cooling equipment winner receives trophy selects charity new riskbased process focused significant installing automatic light receive donation gsk operational ehs risks environmental impacts controllers optimising boiler controls winners excellence awards rather full range applicable ehs demonstrate many projects standards audit frequency determined posters special events improve environmental performance also save considering key site risks demonstrated encourage employees play part employee energy money performance managing effectively wardens also fifth year awards conducted corporate audits sites assigned department help limit energy use entries countries including office locations average score area wardens trained applications gsks business sectors rd percent compared percent identify potential energy manufacturing commercial facilities site achieved score percent savings make sure equipment management teams regard unacceptable aim correct used efficiently unacceptable performance continue pursue raise awareness among winners chosen panel included improvements achieve best practice colleagues experts academia government public site also installed two interest groups projects representing good level performance found kw wind turbines reduce europe north america central america sites especially areas covered gsk amount energy used middle east asia received top honours environmental standards several aspects fossil fuel sources earned identified improvement especially safety issues site four regional awards three first place award winners see health safetypage acted example featured pages see details local industrial complexes ceos ehs excellence award background two sites achieved leadership scores two installed pages percent two similar turbines achieved scores percent seven since barnard castles energy initiatives reduced best performance environmental issues coemissions total tonnes saved audits compliance million management solid wastes project first place request audit committee board air emissions ehs initiative environment directors gsk embarked programme category achieve iso ohsas emergency planning poznan poland certification sites generally weakest poznan site founded gsk science public centre leadership gsks manufacturing self auditing inspection division gms approved fouryear programme centre become meeting venue community certify remaining gms sites iso ohsas risk assessment processes education events public programme began early biodiversity healthcare disease completed sites already prevention community achieved certification one additional compliance education run gsk site certified iso ohsas minimum policy comply legal employees organise bringing total dual certified sites requirements fines penalties activities included means pharmaceutical reported regret helping teachers promote consumer manufacturing sites certified breach regulations three cases prompting healthy behaviour among sites certified iso us federal aviation administration issue students warning letters without penalties regarding non workshops teaching carry regular ehs audits gsk compliance shipping regulations deficiencies pupils operations contract manufacturers key poznan high schools suppliers aim assess well control deal threats risks comply key legislation extent noncompliance marking labelling drugs hivaids management systems standards documentation shipment inhalation aggressive behaviour implemented improve performance aerosols alcohol maintain compliance see supply chainpage inoperative emergency number hazard helping people disabilities put information including human rights information audits theatre performances undeclared dangerous goods flammable local community audit programme requires manufacturing liquid shipped via interoffice mail project first place rd sites undergo ehs audits internal ehs community partnership audit team audits occur every one four years category depending assessment risks sites required develop plans address gsk corporate responsibility report corporate responsibility report material efficiency aim improve efficiency vastly reduces use solvent therefore convert raw materials finished product part waste percent reduction mass drive environmental sustainability help waste avoids tonnes waste us reduce consumption resources per annum waste generate cost production robust previous process set target double average material resulting less waste failed batches efficiency manufacturing processes new reduces exposure employees hazardous products introduced materials achieve material efficiencies percent new processes ie two tonnes active chart shows extent pharmaceutical ingredient api every improving material efficiency compounds move tonnes input chemicals development stages data relate compounds development pharmaceutical processes typically complex often requiring large amounts solvent typically industry uses tonnes material every tonne api produced percent mass productivity distribution material efficiency compares percent fine chemicals percent bulk chemicals represents waste valuable resources financial well environmental consequences approach addressing ehs issues already includes minimising amount material used example ecodesign toolkit see placing higher priority improving use materials bringing together rd manufacturing teams increase material efficiency product development stage well selected existing products key measure material efficiency mass productivity mass materials except water including solvents used process compared mass product produced new percent target applies measure early development almost compounds already making improvements material mass productivity less percent efficiency example research development proportion low level efficiency falls team stevenage uk rd site worked stage last stage development cork ireland site achieve substantial transfer manufacturing majority achieved environmental benefits developing simplified productivity percent process manufacturing dutasteride treatment percent one process achieving benign prostate hyperplasia project productivity percent continue deliver benefits least work third place green chemistry category chief executive officers ehs excellence awards new process produces percent drug substance amount starting material saving millionyear saves energy chemical reaction requires four hours c compared hours c previously gsk corporate responsibility report tnecrep stevenage uk rd site stevenage reduced environmental impacts manufacturing compound development stage original process manufacturing drug involved use seven different solvents number hazardous chemicals produced low yields high waste volumes team stevenage developed new technique tripled material efficiency percent percent reduce waste percent using less organic solvent hazardous chemicals also required less energy majority waste could handled site project first place green chemistrytechnology category stage stage stage stage mass productivity mass productivity mass productivity mass productivity corporate responsibility report product stewardship address environmental issues associated module designed ensure ehs products throughout life cycle begins impacts materials processes services product design continues considered manufacture raw manufacturing eventual disposal refer materials ultimate fate products product stewardship wastes environment section covers product design including see toolkit approach packaging impacts pharmaceuticals product designin background pages environment research development section report covers approach animal testingread environmental issues associated products packaging background pages working improve environmental product design performance packaging across several areas environment health safety staff work product development teams incorporate ehs green packaging guide provides guidance considerations design products business process evaluating selecting sourcing materials identify residual ehs risks packaging options includes interactive products move rd manufacturing wizard known wrap wizard rapid assessment packaging helps packaging ecodesign toolkit designers managers benchmark new developed ecodesign toolkit existing packaging designs considering five metrics scientists engineers use identify process product life cycle improvements address ehs issues early development process toolkit available manufacture material gsk intranet consists five modules mass material green chemistrytechnology guide biodegradability helps gsk scientists engineers apply green chemistry concepts achieve efficient pvc content use resources reduce ehs impacts resource depletion minimise costs example bottles consumer products materials guides containing information lucozade illustrates range work range materials used within gsk packaging operations including solvents avoided one guide covers solvent selection reducing amount packaging moved second deals chemical base glass plastic bottle making huge selection saving weight energy transport costs progressively reduced weight green packaging guide assessment plastic bottle percent tool includes guidance business process evaluating selecting packaging increasing use recycled material bottles options see packaging next currently contain percent recycled material intend increase flascfast lifecycle assessment synthetic percent soon develop chemistry webbased tool process reliable supply allows bench chemists perform streamlined life cycle evaluation environmental improving design facilitate recycling impacts new existing processes based bottles recycling easiest clear bottles materials used flaschelps scientists contaminating residues managers rapidly identify greenest changed coloured clear bottles materials option comparing developed shrink sleeves benchmarking processes identifies need adhesive easily separated materials significant life cycle promoting recycling community environmental impacts provides guidance active members recoup charitable reduce impacts organisation promoting plastics recycling chemicals legislation guide clg uk wwwrecouporg recoup gsk identifies legislation various parts world key contributor study design aimed phasing hazardous substances recycling plastic containers routine use clg provides riskbased funding another project promote recycling guidance variety chemicals plastic containers providing reverse concern easily accessible form vending machines public places gsk corporate responsibility report corporate responsibility report investigating biodegradable plastics also engage joint projects pharma following developments materials ceutical industry pharmaceutical polylactic acid pla made corn starch research manufacturers america phrma currently believe return recycling conventional pet bottles best gsk model used upgrade environmental option pharmaceutical assessment transport using packaging types aim use evaluation phatetm model used best type container product estimate potential environmental impact example use cartons tetra paktmfor sewage sludge applied land phate ribena minimises weight improves used make risk assessments based specific distribution efficiency although recycling local stream flows population patterns systems still development contributed developing database packaging impacts invested scientific literature impacts distribution centre closer bottle pharmaceuticals aquatic life supply company means contributed analysis impact maximise efficiency lorry movements unused medicines environment report shared regulatory agencies developed paper publication scientific literature pharmaceuticals also continue work area environment medicines work active pharmaceutical conducted chronic ecotoxicity testing ingredients apis absorbed patients selected apis based new eu guidelines body materials including anything use guidelines integral part absorbed eventually excreted environmental risk assessment strategy bodys normal mechanisms enter sewage continued comprehensive environmental risk system wastewater treatment plants remove assessments apis developed pharmaceutical residues small concentrations allowable daily intake levels human end rivers sea areas without consumption drinking water fish wastewater treatment higher concentrations enter consumption well noeffects levels environment aquatic organisms make quantitative risk gsk developed business processes ensure assessments comparing levels carry appropriate environmental tests predicted environmental concentrations environmental risk assessments part presented data selected sets approval process new medicines eu compounds scientific meetings us provide regulatory agencies provided data risk assessments assessments evaluate allow mitigation gsk apis swedish association potential environmental impacts pharmaceutical industry lif part part industry groups met voluntary programme provide data regulatory agencies issue including food physicians gsk also part technical drug administration environmental team developed lif guide document protection agency us environment guidance pharmaceutical companies agency england wales risk assessments indicate products appear pose appreciable risk humans see approach pharmaceuticals environment based current methods environmenton background pages ascertaining safe levels continue monitor latest scientific studies findings improve risk assessments area work pharmaceutical companies universities research groups develop science methodologies assess environmental risks pharmaceuticals environment increase understanding risks started investigate issue mixtures pharmaceuticals established relationship brunel university uk develop research plans addition house programme gsk corporate responsibility report corporate responsibility report environmental performance continued improve use energy reduce emissions atmosphere used slightly water generated waste succeeded keeping percentage increase percentage rise sales scope data manufacture pharmaceutical energy efficiency environmental data covers consumer products using processes calendar year need energy discover develop manufacture involve chemicals need collected distribute medicines energy use pharmaceutical consumer understand address report environmental facilities especially manufacturing also manufacturing sites impacts include issues common rd office sites global manufacturing biologicals sites manufacturers use energy water operation pharma waste handling common supply gms research development ceutical consumer research rd accounted percent percent sectors also need consider potential impacts development sites respectively consumption certain chemicals release volatile major office locations concentrating efforts increase include available data sites organic compounds vocs manufacture energy efficiency transport main source operation asthma inhalers also means use chemicals remaining energy use part year damage ozone layer require environmental data improving energy efficiency help reduce small offices distribution reviewed reporting consider global warming impact widely accepted centres materiality environmental impacts light activity humans changing planets pharmaceutical industry practice global notes attached data table climate scientific consensus explain scope reporting initiative well inputs greenhouse gases ghgs carbon dioxide data collection process stakeholders methane causing greenhouse effect parameter detail unless specified per unit stakeholders told us want simplicity trapping heat within earths atmosphere sales figures absolute reporting also need appropriate level causing global increase temperatures burning numbers ie total consumption detail tried balance fossil fuels greatly increased presence energy water etc sometimes conflicting requirements example gases atmosphere experts reduced simplified graphs agree increase ghgs causing earth charts report concentrating areas warm process could bring targets include full data table disastrous changes climate completeness back environment continue working minimise energy use section emissions despite expected growth new concentrate reporting products require additional energy expect continue finding opportunities greater issues potential financial benefit impact efficiencies new existing facilities gsk material efficiency energy operations result new target reduce efficiency energy consumption percent per unit sales issues directly related use chemicals year volatile organic compounds chemical finalised position paperon future oxygen demand wastewater hazardous use energy following extensive internal waste external consultation position paper sets seventh year reported strategy energy efficiency renewable energy gsks environmental performance legacy emissions trading commits gsk companies reported several years reduce reliance fossil fuels whenever creation gsk copies reports technically economically possible available corporate register support effective marketbased mechanisms verification emissions trading seek reduce data environment section emissions first health safety pages employment section report externally verified sgs uk ltd evaluate use renewable energy details found verification statement evaluate energy investments lifetime rather normal payback period used gsk encourage suppliers contractors employees improve energy consumption report transparently energy consumption using internationally recognised protocols gsk corporate responsibility report corporate responsibility report energy performance energy consumption used million gigajoules energy approx imately percent less bought percent energy electricity generated rest target fossil fuels burned sites reduction energy use came despite increase sales energy consumption per sales percent lower baseline continued work energy efficiency initiatives active energy teams manufact uring rd energy managers many larger sites examples include installing energy efficient lighting motion sensors thermographic surveys identify heat losses resulting insulation repairs baseline ultrasonic surveys identify air leaks site voltage reduction projects efficiency improvements heating ventilation air gigajoules per million sales conditioning target retrofitting economisers steam boilers steam trap surveys energy consumption maintenance improvements year gjper million sales electricity steam metering improvements centralised monitoring targeting software systems refrigeration chiller efficiency improvements data table includes additional details energy greenhouse gas emissions amounts renewable energy electricity purchased fuels started invest renewable energy installed combustion capacity required consumed carbon dioxide projects example barnard castle installed participate gsk sites covered equivalent emissions two wind turbines sites using solar balance gsk surplus carbon credits energy sources inhaler production use energy heat water sites purchased proceeds sale carbon credits invested electricity renewable resources energy efficiency projects future report amount electricity energy investments renewable sources adopted approach energy emissions trading investments reflects longterm nature number uk sites participate projects importance energy supply governments emissions trading scheme ets business instead applying normal helping us gain experience carbon trading investment criteria assess return uk ets voluntary scheme rewards investment projects lifetime companies lower energy taxes improve expect result approving energy energy efficiency sites keep emissions efficiency renewable energy projects agreed target bank spare credits help would qualify normal investment comply limits subsequent years criteria sell credits participants scheme first project approved solar water gsk sites complied climate heating site slough uk change agreements european union trading scheme came force start initial threeyear period sites megawatts gsk corporate responsibility report corporate responsibility report transport estimate transport accounts million launched number initiatives reduce kilograms co percent global impact transporting products include warming impact energy consolidating freight shipments pharmaceutical consumer products transported together business air travel accounts almost half consolidating shipping points making use percent travelrelated coemissions round tripping managing inbound freight trucks employees travelled total almost return empty also switch million kilometres plane resulting air sea transport possible million kg coemissions air travel include group travel originating outside uk green travel plans number sites global sales fleet drove total billion encourage employees reduce environmental kilometres business travel resulting impact travel work example gsk million kg co house brentford uk privileged parking spaces given carsharers drivers fuel efficient addition business travel also transport cars buses powered biodiesel run products manufacturing plants local train station changing rooms distributors gsk products showers provided cyclists well discounts transported total million kilometres bicycle equipment repairs beginning majority percent air freight estimate use hybridengine cars chauffeur service air freight resulted million kg cowhile ocean road freight resulted additional encourage employees use video million kg co teleconferencing possible reduce air travel virtual meeting software available employees year used greenhouse gas protocol making presentations collaborative working calculations coemissions also gsk employees conducted able obtain details freight video meetings teleconferences shipments details web conferences precise calculations coemissions freight transport changes unable compare coemissions transport previous years still working obtaining level detail passenger air travel gsk corporate responsibility report corporate responsibility report water performance water consumption used million cubic metres water percent spite small increase water consumption rise sales water consumption per target sales percent lower consumption average industry based benchmarking major pharmaceutical companies baseline water usage gone mainly due increased activity biologicals sites especially higher vaccines production biologicals belgium higher production manufacturing plants ireland uk also required water increases partly offset partial closing one site small improvements several sites result water conservation measures baseline cubic metres per million sales target water consumption year per million sales water use gsk uses water manufacturing processes products cooling cleaning general site uses including drinking food services sanitation primary supply sites manufacture active pharmaceutical ingredients typically heavy users water sites manufacture vaccines produce drinks involved research development commercial activities typically use less water valuable natural resource needs conserved especially areas shortages protected pollution gsk water standard requires sites minimise water use reuse water whenever feasible ensure wastewater treated discharged way minimises adverse environmental impacts target reduce water consumption percent per annum per sales gsk corporate responsibility report corporate responsibility report wastewater performance chemical oxygen demand wastewater generated million cubic metres wastewater total volume percent less reduction partly due changes several sites including target new specialised wastewater treatment facility primary manufacturing plant removes solvent wastewater closure manufacturing operations baseline another plant changes wastewater treatment product mix total chemical oxygen demand cod discharged onsite treatment million kilograms percent less reduction cod per sales percent baseline kilograms per million sales target chemical oxygen demand wastewater year kgper million sales wastewater sites discharge wastewater municipal domestic activity washrooms treatment facilities large sites especially canteens vast majority cod comes primary manufacturing onsite manufacturing contribution wastewater treatment systems sites activities sufficiently significant permitted discharge wastewater direct sea warrant time effort required collect data change may result decrease assess quality wastewater measuring reported cod percent chemical oxygen demand cod oxygen recalculated prior years data required chemically oxidise compounds comparable water lower cod cleaner water target improve cod discharge percent year per sales changed cod measurement concentrate wastewater manufacturing processes exclude sites whose waste mainly gsk corporate responsibility report corporate responsibility report waste research production commercial activities nonhazardous waste produce waste aim manage safely nonhazardous waste general material responsibly generated final office waste paper kitchen waste non disposal want eliminate waste hazardous substances used manufacturing reduce reuse materials small part biological waste possible recycle waste dispose treated hazardous include remaining material sensitively construction demolition rubble similar material related daytoday operations generate different kinds waste different describe separately nonroutine waste parts business continue look ways reduce waste production hazardous wastes solvents undertaken waste management reviews chemicals many sites new target reduce non rd quality laboratories small amounts hazardous waste per sales percent per chemicals including products annum intermediates well broken glassware hazardous waste plastics percent hazardous waste offices paper standard commercial consists solvents used production waste processes also dispose lubricants fluorescent lights research waste includes renovations take place production office animal carcasses lab space produce nonroutine waste obsolete equipment office furniture regulations vary widely around world structural materials first choice solvents reuse recycle material possible main disposal active ingredients pharmaceutical option solvents incineration aim recover products manufactured using chemical energy incineration wherever possible processes means significant proportion waste classified hazardous hazardous waste disposed contains solvents chemicals used processes classify waste hazardous non hazardous nonroutine waste construction demolition rubble baseline production facilities segregate wastes reuse send recycling incinerate landfill anything else incineration usually preferred choice dealing solvents cant reused recycled practicable sites use waste management companies use incinerators recover energy burning materials require disposal contractors comply baseline ehs requirements local regulations sites audit waste contractors hire consultants carry audits kilograms per million sales continue work reducing waste especially target hazardous waste improving material efficiency reduce waste especially number volume hazardous waste disposed solvents set target increase material year kgper million sales efficiency new products going rd manufacturing percent past waste chemicals handling practices contaminated landand groundwater practices longer followed however hazardous waste comes primary continuing clean sites deal production activity concentrate health environmental hazards efforts stopped collecting hazardous waste data consumer manufacturing plants gsk heritage companies spent laboratories offices secondary manufac cleaning sites turing sites sites produced percent us last years continuing clean hazardous waste past sites waste disposal sites gsk one several set target reduction hazardous responsible parties figures included waste target improve material efficiency data verification geared accomplish reductions hazardous waste gsk corporate responsibility report corporate responsibility report waste performance nonhazardous waste disposed generated million kilograms hazardous waste million kilograms nonhazardous waste recycled million target kilograms waste million kilograms hazardous million kilograms non hazardous represents percent total generated excluding non baseline routine waste proportion waste recycled percent lower disposed via landfill incineration million kilograms hazardous waste million kilograms nonhazardous waste total hazardous waste disposed percent higher adjusted rise sales percent lower baseline hazardous waste mostly solvents percent rest general site waste incinerated percent hazardous waste disposed energy recovered percent kilograms per million sales target total nonhazardous waste percent lower amount disposed per sales decreased percent nonhazardous waste disposed year non hazardous waste generated year kgper million sales sent percent landfill recycling recycle hazardous nonhazardous waste two sites india stopped land filling coal aiming minimise environmental impacts well ash generated site instead sell raw cost materials waste material production construction material largest waste component solvent addition three nutritionaldrink manufacturing used manufacturing process sites send process wastes barley husk solvent purified sites reused animal food others recycle canteen waste original manufacturing process sometimes sell effluent treatment plant sludge converting solvent commercial reprocessing companies biocompost also include recycling statistics data table includes additional solvent recycled way usually details waste amounts hazardous incinerated nonhazardous waste go recycling recycling nonhazardous waste paper landfill incineration amount non cardboard glass plastic aluminium usually routine waste means sending reprocessing reused make new products gsk corporate responsibility report corporate responsibility report ozone depletion performance ozone depletion potential total ozone depletion potential odp production inhalers equipment thousand kilograms percent lower based estimates target emissions equipment ozone depletion potential estimated equipment production losses per sales percent lower baseline cfc cfc contained pieces equipment amounting kilograms cfc thousand items equipment contain ozone depleting substances odp kilograms cfc equivalent estimate percent kilograms cfc equivalent released equipment using estimation factor british baseline refrigeration association kilograms per million sales target ozone depletion potential year kgper million sales ozone depletion ozone layer essential human survival chart refers ods lost production filters harmful ultraviolet uv rays activities equipment leakage see data table sun damaged ozone information patient use depleting substances odss mainly chlorofluoro inhalers carbons cfcs hydrochlorofluorocarbons hcfcs installing new equipment help us halons meet target eliminating cfcs main use odss past equipment productuse apart propellant gas metered dose inhalers mdi halon fixed fire protection systems equipment asthma sufferers gas released patients containing one kilogram cfc use inhalers small amount escapes thousand kilograms cfc propellant production past used cfcs released patients used products switching hydrofluorocarbons hfcs dry much smaller amount thousand kilograms powder technology require released production inhalers propellant hfcs deplete ozone layer estimate kilograms cfc equivalent contribute global warming emitted equipment also use odss cooling systems ancillary uses gsk facilities switched using hfcs ammonia hydrocarbons ammonia contribute either ozone depletion global warming hydrocarbons small global warming impact gsk corporate responsibility report corporate responsibility report equipment production metered dose inhalers odss mainly hcfcs sealed inside cooling metered dose inhalersmdis commonly used systems released event leak deliver main forms treatment asthma maintenance sufferers pressurised handheld devices use propellants deliver doses medication way eliminate emissions eliminate patients lungs first introduced cfc hcfc cooling systems cfcs traditionally used new strategy propellant nontoxic nonreactive carried inventory cfc nonflammable odour hcfc containing equipment repeat taste exercise first quarter annually patient uses mdi propellant monitor decrease cfc content released atmosphere montreal also collect data hfcs protocol bans production cfcs exempts recognise also risk catastrophic number essential uses include mdis failure equipment larger releases nevertheless plan eliminate use cfcs eliminate chemicals focusing worldwide product portfolio attention larger pieces equipment stopped using cfcs us remove service end european union offer selection intend replace equipment containing alternatives odscontaining inhalers kilogram less typically countries main alternative propellant use hermetically sealed less likely leak hfc affect ozone longer collect data losses equipment high global warming potential although concentrating eliminating less cfcs also invested heavily dry equipment rather controlling releases powder delivery systems use cfcs comparison prior years estimated hfcs percent total amount cfc hcfc continue manufacture cfc mdis india lost remaining equipment odp china pakistan use subcontractors chart shows emissions producing inhalers produce cfc devices bangladesh latin estimated emissions equipment last america market target year reported kg released based losses eliminate cfcs equipment failures replacements ozone depletion potential patient use metered dose inhalers percent lower previous years information us eu data india pakistan china calculated decrease cfc inhalers produce production cfccontaining mdis decreases amount cfc lost production also declines total ozone depletion potential production percent lower gsk corporate responsibility report corporate responsibility report control volatile organic volatile organic compound emissions compound emissions gsk cork site vocs arise many processes cork use solvents dichloro methane ethyl acetate target ethanol introduction uk air pollution act led focus control elimination solvent emissions carried complete review baseline points emission solvent emissions reactions vacuum pump discharges centrifuges pressure filters tanks collected sitewide system passed two high temper ature incinerators operate c destroy organic vapours efficiency greater percent emissions incinerator baseline stacks continuously monitored voc residues carbon monoxide sulphur oxides nitrogen oxides hydrogen halides incineration operation kilograms per million sales regarded best available target technology efficient destruction vocs prevention emissions substances atmosphere volatile organic compound emissions control voc ulverston year kgper million sales manufacture two intermediate stages antibiotic cefuroxime axetil uses solvents including dichloromethane dcm tetrahydrofuran thf gsk approved project install carbon adsorption unit remove vocs process stages carbon adsorption technology volatile organic selected methodology compounds reduce voc emissions technology offers robust use volatile organic compounds vocs mainly target reduce vocs industry standard abatement solvents primary manufacturing operations percent per annum per sales improvements solution represents best rd pilot plants solvents also used coat voc emissions due several available technology tablets cleaning sterile operations projects primary manufacturing sites capture existing vents air also use small quantities laboratories fugitive emissions changes production redirected carbon measure emissions use changes way voc emissions calculated adsorption unit adsorbed activated alignment local regulations vocs react nitrogen oxides presence carbon bed system operates sunlight creating ozone lower atmosphere photochemical ozone creation potential continuously uses steam regeneration remove results smog factor human percent lower adsorbed solvents respiratory illness workplace exposure certain changed way measure vocs recovered site vocs also pose health risk exclude small quantities laboratories existing solvent recovery unit reuse process released million kilograms vocs estimated percent total voc emissions atmosphere percent lower prior years recalculated voc emissions project remove emissions per sales percent prior years make comparable tonnes per annum dcm releases air lower tonnes per annum thf site also save estimated k per annum recovery reuse solvents gsk corporate responsibility report corporate responsibility report independant verficationassurance statement wwwsgsukltd sgs united kingdom ltds report environment health safety data glaxosmithkline environment health safety ehs report nature scope verificationassurance sgs united kingdom ltd commissioned glaxosmithkline conduct independent assurance ehs report scope assurance based sgs sustainability report assurance methodology included environment health safety performance data graphs contained pages report accompanying table pages data relating contaminated land pages health safety data relating nongsk employees included assurance process financial data drawn directly independently audited financial accounts checked back source part assurance process information ehs report glaxosmithkline presentation responsibility directors management glaxosmithkline sgs united kingdom ltd involved preparation material included ehs report responsibility express opinion data graphs relevant statements within scope verification sgs group developed set protocols assurance sustainability reports based current best practice guidance provided global reporting initiative sustainability reporting guidelines aa assurance standard data report assured using protocol content veracity assurance comprised combination interviews relevant employees evaluation data collection submission methodologies documentation record review validation external bodies andor stakeholders relevant six sites visited uk usa belgium italy singapore eight sites contacted telephone uk usa ireland india australia sites selected included submitting high proportions key data included parts gsk business additionally visits made corporate head quarters webconferencing key individuals utilised order complete verification activities statement independence competence sgs group companies world leader inspection testing verification operating countries providing services including management systems service certification quality environmental social ethical auditing training environmental social sustainability report assurance sgs united kingdom ltd affirm independence glaxosmithkline free bias conflicts interest organisation subsidiaries stakeholders assurance team assembled based knowledge experience qualifications assignment comprised auditors registered irca iema emas verifiers verificationassurance opinion basis methodology described verification work performed satisfied data contained within glaxosmithkline ehs report reliable provides fair balanced representation glaxosmithklines ehs activities believe glaxosmithkline chosen appropriate level assurance stage reporting gsk corporate responsibility report corporate responsibility report independant verficationassurance statement key areas improvement data collection submission manipulation identified follows definitions data submitted always fully understood adhered consistently site level estimations used calculate certain data guidance could provided sites ensure calculations approached consistently establish rigorous process check entered data anomalies data entered error missed data consider incorporation internal audit data data management systems alongside corporate ehs audits ensure training undertaken key individuals replaced ensure consistency full understanding systems requirements ensure sites submit data comments included explain estimations calculations significant changes ensure process used extract data electronic systems used consistently appropriately enable correct values obtained individuals utilising system key areas improvement data verification process identified follows ensure relevant data available internally checked advance external verification process behalf sgs united kingdom ltd pauline earl business manager systems services certification february gsk corporate responsibility report corporate responsibility report global warming potential global warming potential metric gwp energy sources calculated co coequivalent using energy use greenhouse gas ghg energy operations protocol developed million gigajoules world resources institute world business natural gas council sustainable fuels development coal gwp air land steam imported sea transport calculated using ghg protocol electricity imported distance travelled directly fuel used global warming potential coequivalent years gwp operations collect energymillion kilograms categories freight natural gas transport employee business travel fuels missing coal group air travel originated outside uk steam imported motor vehicle travel electricity imported conversion assumes medium vehicles sales employees heavy gwp transportmillion kilograms diesel vehicles freight sales force transport air travel gwp refrigerants product logistics released equipment calculated using factors kyoto protocol gwp production changed activities million kilograms collecting data releases refrigerants inhaler production losses collecting data equipment containing greater amount refrigerant kg refrigerant contained equipment calculating comethane nitrous oxide releases using factor waste treatment british refrigeration sources association probable leakage calculate releases gwp use inhalers refrigeration equipment patientsmillion kilograms holding greater one kilogram refrigerant cfc inhalers gwp ozone cfc inhalers depleting substances hfc inhalers inhalers uses factors kyoto protocol enough water use discharge information calculate water million cubic metres gwp inhaler use previous years municipal wells boreholes water water sources water includes recycled sources wastewater volume million cubic metres ww recycling ww municipal sewer ww water bodies cod onsite treatment million kilograms cod recycled water cod sewer cod water bodies gsk corporate responsibility report corporate responsibility report wastewater metric changed wastewater calculations include wastewater volatile organic compound emissions chemical oxygen demand major volatile organic compound emissions contributors primary million kilograms operations pilot plants pocp total voc emissions coating sterile operations recalculated data previous years top five solvents released million kilograms compared acetone chemical oxygen demand cod measure water dichloromethane pollution manufact methanol uring processes measured wastewater leaves ethanol sites following isopropanol site treatment volatile organic compounds changed ozone depleting substances calculation include ods releases voc major production thousand kilograms contributors primary operations pilot plants cfc releases production coating sterile operations recalcul cfc releases production ated data previous years compared ods releases addition kilograms equipment thousand kilograms voc emitted calculate photochemical ozone cfc releases equipment creation potential pocp cfc releases equipment kilograms ethylene equivalents conversion ods ancillary equipment ethylene equivalents based european chemical industry council ods releases patient use cefic responsible care inhalersthousand kilograms hse reporting guidelines cfc patient use vocs cfc patient use ozone depleting substances ozone depletion potential odp ozone depleting ods contained substances calculated using factors kyoto equipmentthousand kilograms protocol previous years waste generated disposed information inhalers produced asia hazardous waste generated emissions patients use million kilograms previous years hazardous waste recycled information hazardous waste disposed ods amount contained equipment hazardous waste incinerated waste energy recovery consider waste hazardous waste incinerated hazardous radioactive energy recovery bioengineered biohazardous hazardous waste landfill properties defined basel convention includes flammability nonhazardous waste generated explosivity water air million kilograms reactivity corrosivity oxidising potential acute nonhazardous waste recycled chronic toxicity ecotoxicity nonhazardous waste disposed infection biological waste rendered non nonhazardous waste incinerated hazardous treatment energy recovery considered nonhazardous nonhazardous waste incinerated waste energy recovery nonhazardous waste landfill gsk corporate responsibility report corporate responsibility report changed calculation include metric hazardous waste major contributors primary nonroutine waste generated operations pilot plants coating sterile million kilograms operations nonroutine waste recycled recalculated data nonroutine waste disposed previous years compared nonroutine waste incinerated incineration energy energy recovery recovery means burning nonroutine waste incinerated material using energy recovery resulting energy nonroutine waste landfill nonroutine waste includes construction demolition rubble estimated costs investments included hazardous operations maintenance nonhazardous waste calculation cost million injury illness capital investment million health safety data cover employees injury illness gsk employees contract workers directly supervised hours worked millions gsk employees report fatalities snapshot injury number injuries lost time illness performance year cases may calendar days lost injuries added later number illnesses lost time correct prior years calendar days lost illnesses lost time injuries number injuries without lost time illnesses workrelated injuries illnesses number illnesses without lost time serious enough result one days injury illness non gsk employees verified sgs away work hours worked millions lost calendar days fatalities calendar days employees could work number injuries illnesses workrelated lost time injuries illnesses calendar days lost including weekends helps provide measure number injuries illnesses severity injuries without lost time illnesses reportable injuries illnesses without lost time reported incidents result time away work lost time serious first aid generally less serious lost time gsk corporate responsibility report corporate responsibility report work communities make donations money medicines time equipment support underserved communities around world focus investment programmes relevant business skills people improving healthcare education full details criteria giving support available gskcom believe using profits total community investment also includes awards benefit underserved communities part million million cash grants received responsible company also million million management costs world business award supports business international gsk member uks percent club chamber commerce demonstrating commitment tackling companies donate least percent united nations healthcare education challenges pretax profits charitable causes gsk development programme listed sixth uks guardian giving list prince wales making employees feel proud work listed ftse companies percentage international business leaders gsk forum lymphatic pretax profits contributed charitable causes filariasis elimination improving reputation stakeholders fifth year row programme biggest overall giver value donations community investment linked short term excellence corporate business benefits intended create belong uks london benchmarking philanthropy award commercial markets gsk group lbg committee encouraging us based committee corporate philanthropy cecp us report encouraging corporate donations made group level support philanthropy cecp donations line cecp guidelines disease prevention increase healthcare capacity value medicines wholesale acquisition cost frost sullivan developing countries individual gsk sites pharmaceutical companies wholesale global excellence award support local communities malaria prevention acquisition cost wholesale list price treatment total community investment including discounts star business valued million million equivalent commitment education percent pretax profits method giving million award philadelphia education fund objective ensure projects management cash sustainable long term continue costs global health award funding comes end leadership scientific inkind excellence new york community investment made nonprofit academy sciences organisations experts field healthcare education helps ensure platinum ounce award russian pharma giving targeted effectively communities ceutical industry gsk need russia leadership multi coloured lives project value community investment product gsk donations valued million breakdown cash giving million compared million million equivalent percent environment pretax profits compared percent art introduction new medicare prescription culture health drug benefit us meant fewer patients requested help patient assistance programs result donated medicines worth million million lowincome patients us compared million million addition made million million humanitarian product donations underserved communities around world donated albendazole tablets valued million million lymphatic filariasis elimination education programme gsk corporate responsibility report corporate responsibility report investment global public health initiatives greatest contribution make donated million albendazole healthcare developing countries treatments million worth million research new treatments vaccines million valued wholesale prices preferential pricing makes lifesaving medicines countries donated almost million affordable treatments since two new countries joined programme however also help address barriers access medicines investment also gave million million community health programmes grants support global alliance eliminate lf donate money medicines expertise several countries starting integrate lf support initiatives improve healthcare raise programme neglected tropical disease awareness disease prevention developing prevention initiatives extending benefits countries public health zanzibar example taking integrated approach distributing treatments focus five major programmes two parasitic diseases schistosomiasis developing world bilharzia onchocerciasis river blindness founding member global alongside lf treatments alliance eliminate lymphatic filariasis lf country aiming eliminate lf must treat elephantiasis risk people two drugs albendazole positive action programme reduce diethylcarbamazine mectizan year stigma improve capacity hiv aids least five years far egypt several pacific island prevention treatment countries sri lanka zanzibar togo completed five annual mass drug administrations african malaria partnership supporting mobilising malaria advocacy initiative countries monitor populations generate political commitment funding evaluate impact programme combat malaria addition behaviour disease bill melinda gates change initiatives foundation donated million operational research help evaluation phase education programme prevent assessment conducted egypt showed lf diarrhoearelated disease hand eliminated areas country washing gsk global alliance received also donate essential antibiotics world business award international products response humanitarian disasters chamber commerce lf programme support basic healthcare provision impoverished communities mectizan registered trademark merck co initiatives delivered partnership future challenges nonprofit organisations made subsaharan africa presents significant challenge following progress many countries yet commence lf elimination programmes due lack funding eliminating lymphatic filariasis lf health infrastructure countries donating medicine albendazole started lf programmes need additional resources global programme eliminate lf enable scale reach full atrisk wwwfilariasisorg lf disfiguring disease populations additional challenge prevalent tropical countries transmitted integration lf programmes interventions mosquitoes lead severe swelling neglected tropical diseases may involve arms legs breasts genitals thickening coadministration albendazole skin lf one worlds leading causes medicines permanent disability one billion people countries percent positive action hiv aids worlds population risk infection positive action programme set supports communities affected hiv global programme led world health aids aims strengthen capacity organization governments community organisations providing hiv aids endemic countries aims eliminate lf prevention education healthcare services key treating one billion people risk area focus reduce stigma discrimination committed donate free charge many doses major barrier controlling hiv aids albendazole antiparasitic drug used increase number people coming forward prevent transmission lf needed testing treatment recognises involving expect require billions tablets team people affected hiv aids key controlling gsk employees helps global alliance hiv pandemic advocacy research community mobilisation education initiatives supported positive action programmes running countries gsk corporate responsibility report corporate responsibility report activities included scale national hiv prevention efforts asia operating ten countries high hiv prevalence asia tipping point research suggests ukraine russia china india kenya nigeria may catastrophic hiv aids epidemic botswana rwanda belize jamaica region disease prevention treatment efforts information preferential pricing improve access hiv therapies arrangements hiv aids medicines see knowledge use correctly critical effective treatment partnership american foundation aids research gsks african malaria partnership amfar positive action supporting treat asia african malaria partnership supported network clinics hospitals research institutions education behaviour change initiatives eight patient support organisations helping african countries partnerships ngos communities prepare new treatment freedom hunger african medical programmes launched region research foundation amref plan includes community projects china cambodia international since invested thailand vietnam creation regional million million targeting approximately advocacy network two million people fostered effective prevention prompt treatment particularly india surpassed south africa country among young children pregnant women hiv infections world positive action vulnerable malaria funding supporting freedom hungers reach india initiatives come end project aims tackle cultural social support longterm positive impact factors expose women rural india hiv target communities reach india using self help groups established respected means women access however scale malaria problem requires information support educate women significantly bigger response given hiv aids reach women million million grant three years three million family members three years support mobilising malaria advocacy train local organisations delivering education initiative generate greater awareness political projects commitment sustained funding combat disease national coalitions malaria mexico launched uk belgium france ethiopia second year project cameroon bringing together advocates international hiv aids alliance colectivo activists public sector ngos media sol mexico reduce stigma discrimination private sector political academic associated hiv aids thirteen community scientific communities organisations help people living hiv aids including gay men sex workers drug gsk frost sullivan global users joined project colectivo sol excellence award malaria prevention helping identify impact stigma treatment judges noted gsk made hiv transmission access services work facing challenge malaria key corporate address advocacy media responsibility issue using core business skills local police health services government resources well philanthropic community programs contribute global efforts tackle africa disease committed million million three years strengthen integrate hiv personal hygiene sanitation aids treatment general healthcare clinics education phase kenya enable patients avoid stigma every year two million people die visiting dedicated hiv clinic help diarrhoearelated disease mostly children doctors provide ongoing services people developing countries deaths often diagnosed hiv positive action working easily prevented better hand washing clinics third sites currently sanitation offering arv treatment kenya identify phase helping reduce diarrhoearelated successful approaches improving takeup disease encouraging school children wash arv treatment hands established phase global since invested million sponsored global village community million programme exhibition workshop area international phase run partnership amref plan aids conference held toronto canada international save children well highlighted key issues affected communities ministries health education stimulated dialogue networking among countries global community around people attended also supporting project international council aids service organizations icaso boost communitybased advocacy gsk corporate responsibility report corporate responsibility report approach donations programme impressive results investment medicines example evaluation data sample phase gsk follows world health schools nicaragua four year period show local programmes organization interagency frequency hand washing using guidelines drug donations support wide range health education toilet among pupils participating schools state donations initiatives communities operate increased fivefold proportion children donations made centrally sites reporting diarrhoea two week period fell made response response local needs percent percent expressed need examples many sent prior consent bangladesh joined phase community partnerships supported major implemented schools reaching labelled correctly regions children far integrated school minimum oneyear health nutrition programme save supporting health shelf life children phase partner bangladesh europe donate medicines addition longterm support hole diseases require phase extended mexico tajikistan wall childrens camps barretstown ireland continuous assured supply operates eight countries lenvol france giving total number children reached phase active member programmes five european partnership quality medical estimated countries improve childrens healthcare donations pqmd alliance future challenges pharmaceutical companies major country programmes charities encourages plan launch phase kibera kenya africas best practice donation largest slum first time phase italy reading growing reading aloud delivery medicines operated informal settlement creating programme children neurofunctional model improving childrens health one disabilities hardest urban communities romania beacon hope palliative care humanitarian relief programme children multicoloured lives russia support multicoloured lives gsk donates essential products antibiotics slovakia change advance disease help improve quality help relief efforts disaster areas support prevention programme children urban life disabled children russia basic healthcare provision impoverished housing estates programme brings together communities regional charity community spain childrens shelters providing healthcare foundation government donations made request governments homeless abandoned children moscow gsk russia six major charitable organisations may thousand children aged manufactured specifically partners russia multicoloured lives see sidebar years old limited health enables charities hold range medicines capabilities taking part international stock respond promptly multicoloured lives using support major public health initiatives tackle emergency work partnership several communitybased communi hiv aids lymphatic filariasis malaria relief charities including americares direct relief cations tv magazines diarrhoearelated diseases developing countries workshops schools liaison interchurch medical assistance map international exhibitions educate project hope addition funding countryspecific gradually change individuals programmes grant activity perceptions disabled people three years donated lifesaving medicines gsk russia received platinum worth million million valued wholesale country programmes international ounce award leadership prices support relief efforts community region include multicoloured lives russian pharmaceutical industry healthcare countries brazil attituda positiva uses drama schools requests medicines sometimes made educate teenagers hiv good help people affected conflict reproductive health controversial requires careful management philippines pinoy health pass family health seek ensure equitable treatment approach well provides health education directing commitment support health needs families low incomes provision long term support work partners get essential drugs doctors uk patients clinics hospitals gsk supported charitable organisations uk included example made four shipments million support medical research medicines support people displaced asthma uk british retinitis pigmentosa conflict lebanon response specific society deafness research uk muscular requests humanitarian aid partners dystrophy campaign provided supplies augmentin amoxil zinacef zantac lanoxin valued products handled partners americares ima direct relief gsk corporate responsibility report corporate responsibility report donations support health charities vietnam midwives included since princess royal trust carers since gsk france foundation supporting unique training programme based tu du hospital initiative donation supported programmes countries hospital ho chi minh city years develop guidelines focus people living hiv aids vietnam project training support gps hospitals working developing countries aim improve healthcare birth attendants provide carers prevention education training maternal healthcare services new programmes implemented rural villages project aims myasthenia gravis association donation six countries grants reduce childbirth complications three years decrease newborn fatality provide specialist nurses people suffering gsk foundation canada focuses hospice unacceptably high level myasthenia gravis chronic auto care helping terminally ill patients families percent immune neuromuscular disorder foundation also supports community supported tu du medical programmes africa including aids orphans nursing staff housed within downs syndrome association shifting uganda threeyear programme building residential training centre built perspectives support gsk trainees spend four community support vulnerable children photographic exhibition showing people months gaining practical luweero district working african medical downs syndrome lead full rewarding knowledge maternal semiindependent lives research foundation amref child healthcare midwives graduated north carolina gsk foundation usa impact awards recognise community governmentrecognised endowed selffunding organisation supports organisations whose work significantly qualification midwife initiatives areas mathematics science equipped medical improved health year award health education north carolina pack provided range healthcare charities foundation awarded grants totalling million motor scooter assist selected panel judges hartlepool million access remote areas families first judged overall winner work bringing health services deprived areas crisis open christmas hartlepool refitted doubledecker bus crisis open christmas offers much needed support us supporting education homeless people across london increasing support zone health festive season school obesity programme run north gsk supports education uk us supported crisis carolina prevention partners following pilot particular emphasis making science following ways programme successfully reached relevant young people supporting donations food children professional development science teachers clothing gsk employees programme provides elementary middle education programmes help increase donation christmas high schools north carolina philadelphia pool potential future employees encouraging card challenge campaign instead sending corporate learning model encourage healthy weight young people pursue science careers christmas cards nutrition education exercise new component programme include distance science education uk donation learning puppets talking scienceengaging scienceis new cover operating costs initiative launched sponsored gsk mobile medical service programmes support us uses puppets increase childrens visits crisis centres include understanding science childrens health funds referral research nuffield foundation found management initiative rmi helps high teachers used puppets science lessons risk homeless children receive specialist children treated real characters medical care need puppets engaged pupils helping solve science problems result children recognise excellence community talked science increased healthcare philadelphia area understanding subject particularly us glaxosmithkline impact awards year noticeable among low achieving children ten nonprofit organisations receive normally speak lessons typical help continue remarks included like talking group work friends teacher understand much better foundations puppets gsk operate single charitable foundation invested community investment programmes train teachers uk primary schools countrybased foundations canada czech use puppets effectively science lessons republic france italy romania spain north schools also receive book science based carolina us local foundations support stories animated cd two hand held wide range charities healthcare initiatives puppets story two puppets faced problem science theme ask children help solve gsk corporate responsibility report corporate responsibility report announced funding crest cid employee involvement investigators education project programme run partnership british association encourage employees contribute advancement science provide science local communities volunteers benefits activities awards school clubs community employees gain new primary schools aim schools experiences skills children taking part hundreds employees give time good support inspire innovative scheme causes days caring us postdoctoral researchers research support school science education education enables postdoctoral researchers uk science engineering ambassador scheme spend half time specialist science schools us partnership educational discovery gain postgraduate certificate education uk us make cash donations pgce charities employees done voluntary education us work founding partner institute gsk investment volunteer excellence competitive workforce business coalition run give programme gave us chamber commerce improve charities us employees educational standards partnerships partners volunteered least hours business education providers making difference programme working national board provided grants professional teaching standards nbpts charities employees providing scholarships endowment volunteered million increase number science teachers national board certified many countries encourage employees far focussed north carolina donate money charity matching money philadelphia expanded give providing taxefficient ways states make donation accordance local taxation guidelines support range local education initiatives us help engage young students science us gsk matched donations examples include employees retirees value million million addition gsk gave science summer free million match donations gsk programme philadelphia giving employees annual gsk united children chance participate way campaign handson experiments science courses major sponsor university north carolinas travelling science laboratory destiny since inception destiny serves approximately underserved secondary schools reaches students per year gsk corporate responsibility report corporate responsibility report data summary access medicines number countries supplied preferentially priced arvs number preferentially priced combivirand epivirtablets shipped millions number generic arvs supplied gsk licencees millions gsk combivirnotforprofit price per day voluntary licences granted generic manufacturers gsk arvs cumulative total value products donated gsk patient assistance program us millions research development expenditure rd billions gsk animal research facilities accredited association assessment accreditation laboratory animal care number trials published gsk clinical trial register cumulative total ethical conduct number managers completing certification gsk code conduct number contacts ethics compliance channels employment women management grades ethnic diversity minorities us ethnic diversity ethnic minorities uk lost time injury illness rate cases per hours worked environment number contract manufacturers audited energy consumption million gigajoules water consumption million cubic metres ozone depletion potential metered dose inhalers tonnes cfc equivalent ozone depletion potential production tonnes cfc equivalent ozone depletion potential refrigeration ancillary uses tonnes cfc equivalent volatile organic compound emissions thousand tonnes global warming potential energy sources thousand tonnes co equivalent hazardous waste disposed thousand tonnes community investment total community investment expenditure millions value humanitarian product donations including albendazole millions number albendazole tablets donated prevention lymphatic filariasis millions includes arvs sold notforprofit discounted prices unable collect data number patients treated includes delivery costs mdecins sans frontires pricing report lists average cost generic equivalents covers animals used gsk facilities animal research laboratories closed laboratory japan aquired laboratories croatia canada established contracts use laboratories singapore us making current total gsk laboratories use animals trials completed since merger created gsk includes contacts line managers compliance officers confidential integrity helplines offsite post office box us data include inhalers made asia changed way calculate data previous years data reflect change see full environmental report details trademarks brand names appearing italics throughout publication trademarks either owned andor licensed gsk associated companies gsk corporate responsibility report